

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	PROTOCOL ACTIVATED	PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2017)			
S0421	Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421. G Sonpavde, GR Pond, M Plets, CM Tangen, MHA Hussain, PN Lara, Jr, A Goldkorn, MG Garzotto, PC Mack, CS Higano, NJ Vogelzang, IM Thompson, Jr, PW Twardowski, PJ Van Veldhuizen, Jr, N Agarwal, MA Carducci, J Monk, DI Quinn. <u>Clinical Genitourinary Cancer</u> , 2017 May 10 [Epub ahead of print]. PMID28579151 https://www.ncbi.nlm.nih.gov/pubmed/28579151	8/21/06	5/1/10
S1014	Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction. TW Flaig, M Plets, M Hussain, N Agarwal, N Mitsiades, HA Deshpande, U Vaishampayan, IM Thompson. <u>JAMA Oncology</u> 2017 Mar 30 [Epub ahead of print]. PMID28358937 https://www.ncbi.nlm.nih.gov/pubmed/28358937	8/9/11	8/1/13
S1602	Bacillus Calmette-Gue'rin manufacturing and SWOG S1602 Intergroup clinical trial [editorial] . JJ Meeks, SP Lerner, Robert S. Svatek. <u>Journal of Urology</u> Mar; 197(3 Pt 1):538-540, 2017. 2016 Dec 16. [Epub ahead of print]. PMID27992750; PMC n/a – editorial. https://www.ncbi.nlm.nih.gov/pubmed/27992750	(pending activation)	
S8710	Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. E Ojerholm, A Smith, W-T Hwang, BC Baumann, KN Tucker, SP Lerner, R Mamtani, B Boursi, JP Christodouleas. <u>Cancer</u> , 2017 Mar 1;123(5):794-801. doi: 10.1002/cncr.30422. Epub 2016 Oct 27. PMID27787873; PMC5319875 https://www.ncbi.nlm.nih.gov/pubmed/27787873	8/1/87	7/1/98
E2805	Retroperitoneal lymphadenectomy in high-risk non-metastatic renal cell carcinoma: an analysis of the ASSURE (ECOG 2805) Adjuvant Trial. B Ristau, J Manola, N Haas, DY Heng, EM Messing, CG Wood, C Kane, R DiPaola, R Uzzo. <u>Journal of Urology</u> 2017 Jul 17 [Epub ahead of print]. PMID28728992 https://www.ncbi.nlm.nih.gov/pubmed/28728992		

GU MANUSCRIPTS SUBMITTED (2017)

S0337	Immediate Post TURBT Instillation of Gemcitabine vs Saline for Suspected Low Grade Bladder Cancer: SWOG S0337. EM Messing, CM Tangen, SP Lerner, DM Sahasrabudhe, TM Koppie, DP Wood, Jr, PC Mack, RS Svatek, CP Evans, KS Hafez, DJ Culkin, TC Brand, LI Karsh, JM Holzbeierlein, SS Wilson, G Wu, M Plets, NJ Vogelzang, IM Thompson, Jr. JAMA, submitted 9/13/17.		
S0421	Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: results from SWOG S0421. PN Lara, Jr., M Plets, C Tangen, E Gertz, NJ Vogelzang, M Hussain, PW Twardowski, MG Garzotto, JP Monk, M Carducci, A Goldkorn, PC Mack, DI Quinn, IM Thompson, M Van Loan. <u>Clinical Cancer Research</u> , submitted.	8/21/06	5/1/10
S0925	Circulating microRNAs and treatment response in SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. HH Cheng, M Plets, H Li, CS Higano, CM Tangen, N Agarwal, NJ Vogelzang, M Hussain, IM Thompson, Jr., M Tewari, EY Yu. <u>Prostate</u> , pending revision/resubmission.		
S1107	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. PW Twardowski, CM Tangen, X Wu, MR Plets, ER Plimack, N Agarwal, NJ Vogelzang, J Wang, S Tao, IM Thompson Jr., P Lara Jr. <u>Clinical Cancer Research</u> , submitted .		

GU ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017)

S0337	A phase III blinded study of immediate post-TURBT instillation of gemcitabine versus saline in patients with newly diagnosed or occasionally recurring grade I/II non-muscle invasive cancer: SWOG S0337. EM Messing, C Tangen, DM Sahasrabudhe, TM Koppie, DP Wood, Jr., PC Mack, RS Svatek, CP Evans, KS Hafez, DJ Culkin, TC Brand, LI Karsh, JM Holzbeierlein, SS Wilson, G Wu, M Plets, SP Lerner, NJ Vogelzang, IM Thompson, Jr. AUA Annual Meeting (May 12-16, 2017, Boston, MA), oral. <u>Journal of Urology</u> Vol. 197, No. 4S, Supplement, PNFLBA-10, 2017. http://www.jurology.com/article/S0022-5347(17)39232-7/fulltext	7/15/07	8/15/12
S0931	Everolimus (EVE) exposure as a predictor of toxicity in renal cell cancer (RCC) patients (pts) in the adjuvant setting: results of pharmacokinetic analysis initial results for from SWOG S0931 (EVEREST), a phase III study (ClinicalTrials.gov Identifier: NCT01120249). TW Synold, M Plets, C Tangen, E Heath, GS Palapattu, PC Mack, MN Stein, MV Meng, NJ Vogelzang, I Thompson, P Lara, Jr., N Vogelzang, Ian M. Thompson, Jr., CW Ryan. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), accepted, poster. <u>J Clin Oncol</u> 35, 2017 (suppl; abstr 4566). http://abstracts.asco.org/199/AbstView_199_190176.html		
S1107	Exome Sequencing of Tumor Tissue Samples Collected from Patients Participating in SWOG S1107 "Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ-197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell carcinoma (pRCC). P Twardowski, X Wu, C Tangen, E Plimack, N Agarwal, M Plets, N Vogelzang, J Wang, S Tao, IM Thompson, Jr., P Lara. European Society for Medical Oncology (ESMO) (September 8-12, 2017, Madrid, Spain), poster.	8/20/12	
S1500	A randomized, phase II efficacy assessment of multiple MET kinase inhibitors (Cabozantinib [NSC #761968], crizotinib [NSC #749005], savolitinib [NSC #785348], and sunitinib [NSC #736511]) in metastatic papillary renal carcinoma (PAPMET): SWOG S1500, NCT02761057. SK Pal, C Tangen, IM Thompson, Jr., B Shuch, N Balzer- Haas, DJ George, M Stein, M Plets, P Lara, Jr. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; <u>J Clin Oncol</u> 35, 2017 (suppl; abstr TPS4599). http://abstracts.asco.org/199/AbstView_199_187390.html		
S1605	SWOG S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. P Singh, C Tangen, S Lerner, D McConkey, M Plets, S Lucia, M Woods, T Bivillacqua, W Kassouf, R Bangs IM Thompson, Jr., PC Black. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), accepted, poster session. <u>J Clin Oncol</u> 35, 2017 (suppl; abstr TPS4591). http://abstracts.asco.org/199/AbstView_199_184714.html	2/7/17	

S1605	S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. P Singh, S Lerner, D McConkey, S Lucia, W Kassouf, M Woods, T Bivillacqua, M Plets, C Tangen, PC Black. Canadian Urological Association annual meeting (June 24-27, 2017, Toronto, Ontario, Canada), poster. <u>Canadian Urological Association Journal</u> June Volume 11(6Suppl4), abst. MP-04.15, 2017. http://www.cuaj.ca/index.php/journal/article/view/4728/3190	2/7/17	
S9921	Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high risk prostate cancer (PCa) patients following radical prostatectomy. A phase III Intergroup Trial (SWOG S9921) NCT00004124. LM Glode, CM Tangen, M Hussain, GP Swanson, DP Wood, W Sakr, NA Dawson, NB Haas, TW Flaig, TB Dorff, DW Lin, ED Crawford, DI Quinn, NJ Vogelzang, IM Thompson Jr. ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), oral. <u>Journal of Clinical Oncology</u> 35, 2017 (suppl 6S; abstract 2). http://meetinglibrary.asco.org/content/178809-197	10/15/99	1/12/07
S9921	Adjuvant androgen deprivation (AD) +mitoxantrone + prednisone (MP) in high risk prostate cancer (PC) patients post radical prostatectomy (RP): phase III intergroup trial S9921. M Hussain, C Tangen, IM Thompson Jr., GP Swanson, D Wood, W Sakr, NA Dawson, NB Haas, TW Flaig, TB Dorff, DW Lin, ED Crawford, DI Quinn, NJ Vogelzang, LM Glode. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 35, 2017 (suppl; abstr 5019). http://abstracts.asco.org/199/AbstView_199_183222.html	10/15/99	1/12/07
E3805	Impact of metformin on overall and prostate cancer-specific survival in the chemohormonal adjuvant chemotherapy CHARTED trial. D Jarrard, YH Chen, G Liu, M Carducci, M Eisenberger, YN Wong, L Patrick-Miller, N Hahn, M Kohli, M Cooney, R Dreicer, NJ Vogelzang, J Picus, D Shevrin, M Hussain, J Garcia, R Dipaola, C Sweeney. ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), poster. <u>Journal of Clinical Oncology</u> 35, 2017 (suppl 6S; abstract 181). http://meetinglibrary.asco.org/content/179540-197	9/1/08	11/21/12
E3805	Burden of metastatic hormone sensitive prostate cancer identifies men more likely to benefit from early docetaxel. G Gravis, JM Boher, YH Chen, G Liu, K Fizazi, M Carducci, S Oudard, R Dipaola, F Joly, D Jarrard, M Soulié, M Eisenberger, M Habibian, R Dreicer, NJ Vogelzang, M Hussain, M Kohli, J Garcia, J Picus, C Sweeney. ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), poster. <u>Journal of Clinical Oncology</u> 35, 2017 (suppl 6S; abstract 136). http://meetinglibrary.asco.org/content/178873-197	9/1/08	11/21/12

E3805	Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D). LC Harshman, Y-H Chen, G Liu, M Carducci, D Jarrad, M Eisenberger, Y-N Wong, N Hahn, M Kohli, M Conney, R Dreicer, NJ Vogelzang, J Picus, D Shevrin, M Hussain, J Garcia, R Dipaola, CJ Sweeney. ASCO GU Cancers Symposium (February16-18, 2017, Orlando, FL), poster. <u>Journal of Clinical Oncology</u> 35, 2017 (suppl 6S; abstract 137) http://meetinglibrary.asco.org/content/178954-197	9/1/08	11/21/12
EA8143	A phase 3 randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC, EA8143). LC Harshman, M Puligandla, NB Haas, M Allaf, D McDermott , S Signoretti , R Gupta, TK Choueiri , P Lara, A Kapoor, D Heng, B Shuch, M Jewett, D George, D Michaelson, R Bhatt, E Van Allen , V Master, MA Carducci. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session, TIP; J Clin Oncol 35, 2017 (suppl; abstr TPS4596). http://abstracts.asco.org/199/AbstView_199_183726.html	2/2/17	

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	PROTOCOL ACTIVATED	PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2016)			
S8710/Multiple	Validating a local failure risk stratification for use in prospective studies of adjuvant radiation therapy for bladder cancer. Baumann B, He J, Hwang W, Tucker KN, Bekelman JE, Herr H, Lerner SP, Guzzo TJ, Malkowicz SB, Christodouleas J. <u>International Journal of Radiation Oncology, Biology, and Physics</u> Jun 1;95(2):703-706, 2016. PMID27020106. http://www.ncbi.nlm.nih.gov/pubmed/27020106 [S8710, OTHER]	n/a	n/a
S9346_Other	Evaluating intermittent androgen deprivation therapy phase III clinical trials: "The devil is in the details." M Hussain, C Tangen, C Higano, N Vogelzang, I Thompson. <u>Journal of Clinical Oncology</u> , Jan 20;34(3):280-285, 2016. PMID26552421; Special Article (PMC Journal – In Process) http://www.ncbi.nlm.nih.gov/pubmed/26552421	5/15/95	9/1/08
S9916_S4021 Multiple	A meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, M Rosenthal, DP Petrylak, M Hussain, NJ Vogelzang, IM Thompson, KN Chi, J de Bono, AJ Armstrong, MA Eisenberger, A Fandi, S Li, JC Araujo, CJ Logothetis, DI Quinn, MJ Morris, CS Higano, IF Tannock, EJ Small. <u>Journal of Clinical Oncology</u> , 2016 May 10;34(14):1652-1659; 2016 Mar 7 [Epub ahead of print]. PMID26951312; PMC4872320 http://www.ncbi.nlm.nih.gov/pubmed/26951312	n/a	n/a
E2805	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, JP Dutcher, MB Atkins, M Pins, G Wilding, D Cella, L Wagner, S Matin, TM Kuzel, WJ Sexton, Y-Ni Wong, TK Choueiri, R Pili, I Puzanov, M Kohli, W Stadler, M Carducci, R Coomes, RS DiPaola. <u>Lancet</u> May 14;387(10032):2008-2016, 2016. 2016 Mar 8 [Epub ahead of print]. PMID26969090; PMC4878938 http://www.ncbi.nlm.nih.gov/pubmed/26969090	5/15/06	9/1/10
Multiple*	Summary and recommendations from the National Cancer Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. SP Lerner, DF Bajorin, CP Dinney, JA Efsthathiou, S Groshen, NM Hahn, D Hansel, D Kwiatkowski, M O'Donnell, J Rosenberg, R Svatek, JS Abrams, H Al-Ahmadie, AB Apolo, J Bellmunt, M Callahan, EK Cha, C Drake, J Jarow, A Kamat, W Kim, M Knowles, B Mann, L Marchionni, D McConkey, L McShane, N Ramirez, A Sharabi, AH Sharpe, D Solit, CM Tangen, AT Amiri, E Van Allen, PJ West, JA Witjes, D Quale. <u>Bladder Cancer</u> Apr 27;2(2):165-202, 2016. PMID27376138; PMC4927845 http://www.ncbi.nlm.nih.gov/pubmed/27376138 *includes SWOG studies S0337, S0353, S1314, S1602, S8507	n/a	n/a

GU ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2016)

S0421	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG study S0421. GR Pond, G Sonpavde, M Plets, CM Tangen, MH Hussain, PN Lara , A Goldkorn, M Garzotto, P Mack, C Higano N Vogelzang, IM Thompson, P Twardowski , P Van Veldhuizen , N Agarwal, M Carducci, JP Monk, Quinn DI. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 5079). http://abstract.asco.org/176/AbstView_176_166577.html	8/21/06	5/1/10
S0421	Bone biomarkers and overall survival (OS) in men with castration resistant prostate cancer (CRPC) and skeletal metastases: updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan. PN Lara, Jr., M Plets, C Tangen, E Gertz, NJ Vogelzang, DI Quinn, I Thompson, M Van Loan. European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark), poster presentation; Annals of Oncology vol. 27, 2016 Supp 6, abstr. 754P. http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf	8/21/06	5/1/10
S1216	Circulating tumor cells (CTCs) in SWOG S1216: a phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). A Goldkorn, M Plets, N Agarwal, M Hussain, P Lara, D Vaena, GR MacVicar, T Crispino, A Harzstark, P Twardowski, C Tangen, C Hugen, T Xu, Y Xu, J Pinski, S Ingles, C Higano, N Vogelzang, I Thompson, D Quinn. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster discussion. J Clin Oncol 34, 2016 (suppl; abstr 11516) http://abstract.asco.org/176/AbstView_176_164681.html	3/1/13	n/a
E3805	Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHARTED trial. Sweeney C, Chen Y-H, Liu G, Carducci M, Jarrard D, Eisenberger M, Wong Y, Patrick-Miller L, Hahn N, Kohli M, Conney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R. European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark) <u>Annals of Oncology</u> vol. 27, 2016 Supp 6:abstr.720PD, 2016. http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf		
E3805	Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa). M Pomerantz, V Wang, P Kantoff, W Xie, M Kohli, G-S M Lee, E Wang, Y-H Chen, N Hahn, D Jarrard, G Liu, J Garcia, M Carducci, RS DiPaola, M Freedman, CJ Sweeney. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 1540). http://abstract.asco.org/176/AbstView_176_170312.html	9/1/08	11/21/12
E3805	Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHARTED trial.	9/1/08	11/21/12

C Sweeney, Y-H Chen, G Liu, M Carducci, D Jarrard, M Eisenberger, Y-N Wong, L Patrick-Miller, N Hahn, M Kohli, M Conney, R Dreicer, NJ Vogelzang, J Picus, D Shevrin, M Hussain, J Garcia, R Dipaola. European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark), accepted, poster presentation. Annals of Oncology vol. 27, 2016 Supp 6, abst. 720PD.

<http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf>

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	PROTOCOL ACTIVATED	PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2015)			
4B951	Variability in surgical quality in a phase III prospective clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. DA Mata, S Groshen, F-C von Rundstedt, DG Skinner, WM Stadler, RJ Cote, JP Stein, SP Lerner. <u>Journal of Surgical Oncology</u> Jun;111(7):923-928, 2015. PMID 25873574; PMC4602027 http://www.ncbi.nlm.nih.gov/pubmed/25873574	10/15/01	3/28/06
4B951	Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. F von Rundstedt, DA Mata, S Groshen, JP Stein, DG Skinner, WM Stadler, RJ Cote, ON Kryvenko, G Godoy, SP Lerner. <u>British Journal of Urology International</u> 116(1):44-49, 2015. PMID25413313; PMC4524781 http://www.ncbi.nlm.nih.gov/pubmed/25413313	10/15/01	3/28/06
S0421	Circulating tumor cell telomerase activity as a prognostic marker for overall survival in metastatic castration resistant prostate cancer: results from SWOG S0421. A Goldkorn, B Ely, C Tangen, Y-C Tai, T Xu, H Li, P Twardowski, P Van Veldhuizen, N Agarwal, M Carducci, J Monk, M Garzotto, P Mack, P Lara, C Higano, M Hussain, N Vogelzang, IM Thompson, R Cote, D Quinn. <u>International Journal of Cancer</u> . Apr 15;136(8):1856-62, 2015. [Epub 2014 Oct 8.]. PMID25219358; PMC4323674 http://www.ncbi.nlm.nih.gov/pubmed/25219358	8/21/06	5/1/10
S0925	SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. EY Yu, H Li, CS Higano, N Agarwal, SK Pal, A Alva, EI Heath, ET Lam, S Gupta, MB Lilly, Y Inoue, KN Chi, NJ Vogelzang, DI Quinn, HH Cheng, SR Plymate, M Hussain, CM Tangen, IM Thompson, Jr. <u>Journal of Clinical Oncology</u> May 10;33(14):1601-8,2015. PMID25847934; PMC4417730 http://www.ncbi.nlm.nih.gov/pubmed/25847934	12/15/10	12/1/12
E2804	BEST: A randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma-a trial of the ECOG-ACRIN Cancer Research Group (E2804). K Flaherty, J Manola, M Pins, DF McDermott, MB Atkins, JJ Dutcher, DJ George, KA Margolin, RS DiPaola. <u>Journal of Clinical Oncology</u> Jul 20;33(21):2384-2391, 2015. PMID26077237; PMC4500832 http://www.ncbi.nlm.nih.gov/pubmed/26077237	4/1/08	12/10/10

E2805	Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805. NB Haas, J Manola, B Ky, KT Flaherty, RG Uzzo, CJ Kane, M Jewett, L Wood, CG Wood, MB Atkins, JJ Dutcher, G Wilding, RS DiPaola. <u>Clinical Cancer Research</u> 21(18):4048-4054, 2015. PMID25967143; PMC4573791 http://www.ncbi.nlm.nih.gov/pubmed/25967143	5/15/06	9/1/10
E3805	Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. C Sweeney, Y-H Chen, M Carducci, G Liu, D Jarrard, Y-N Wong, M Eisenberger, N Hahn, M Kohli, M Cooney, R Dreicer, N Vogelzang, J Picus, D Shevrin, M Hussain, J Garcia, R DiPaola. <u>New England Journal of Medicine</u> Aug 20;373(8):737-746, 2015; 2015 Aug 5 [Epub ahead of print]. PMID26244877; PMC4562797 http://www.ncbi.nlm.nih.gov/pubmed/26244877	9/1/08	11/21/12
CCTG PR3	Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. MD Mason, WR Parulekar, MR Sydes, M Brundage, P Kirkbride, M Gospodarowicz, R Cowan, EC Kostashuk, J Anderson, G Swanson, MK Parmar, C Hayter, G Jovic, A Hiltz, J Hetherington, J Sathya, JB Barber, M McKenzie, S El-Sharkawi, L Souhami, PD Hardman, BE Chen, P Warde. <u>Journal of Clinical Oncology</u> 2015 Jul 1;33(19):2143-50. Epub 2015 Feb 17. PMID25691677; PMC4477786 https://www.ncbi.nlm.nih.gov/pubmed/25691677	11/1/96	8/31/05

GU ABSTRACTS PUBLISHED/PRESENTED (2015)

S0421	SWOG 0421: Impact of circulating markers of bone metabolism on overall survival in men with metastatic castration resistant prostate cancer (CRPC). PN Lara, Jr., M Plets, C Tangen, E Gertz, DI Quinn, I Thompson, M Van Loan. European Multidisciplinary Meeting on Urological Cancers (EMUC) (November 12 -15, 2015, Barcelona, Spain), submitted 7/1/15; accepted, oral presentation.	8/21/06	5/1/10
S1011	A phase III surgical trial to evaluate the benefit of a standard versus an extended pelvic lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer: SWOG S1011 (NCT #01224665). SP Lerner, C Tangen, RS Svatek, TM Koppie, A Alva, FG LaRosa, SK Pal, S Daneshmand, CPN Dinney, AS Kibel, K Pohar, DJ Canter, W Kassouf, R Bangs, IM Thompson. American Urological Association (May 15-19, 2015, New Orleans), moderated poster presentation; <u>Journal of Urology</u> , Vol. 193, Issue 4, e807 [abst MP65-02]. http://www.jurology.com/article/S0022-5347(15)02603-8/pdf	8/1/11	n/a
S1014	Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. TW Flaig, CM Tangen, MHA Hussain, N Agarwal, N Mitsiades, H Deshpande, U Vaishampayan, IM Thompson. ASCO GU Cancers Symposium (February 26-28, 2015, Orlando, FL), poster presentation; <u>Journal of Clinical Oncology</u> 33(suppl 7; abstr 152), 2015. http://meetinglibrary.asco.org/content/123863-142	8/9/11	8/1/13

S1107	SWOG 1107: Parallel randomized phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (pts) with advanced papillary renal cell carcinoma (pRCC). PW Twardowski, M Plets, ER Plimack, N Aggarwal, CM Tangen, NJ Vogelzang, IM Thompson, Jr, PN Lara, Jr.. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion. <u>J Clin Oncol</u> 33:5s (suppl; abstr 4523), 2015. http://abstracts.asco.org/156/AbstView_156_143218.html	8/20/12	5/29/14
E2805	Results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. NS Balzer-Haas, J Manola, RG Uzzo, MB Atkins, G Wilding, M Pins, MA Jewett, CJ Kane, D Cella, LI Wagner, R Coomes, CG Wood, JJ Dutcher, KT Flaherty, RS DiPaola. ASCO GU Cancers Symposium (February 26-28, 2015, Orlando, FL), general poster session. <u>Journal of Clinical Oncology</u> 33 (suppl 7; abstr 403), 2015. http://meetinglibrary.asco.org/content/141765-159	5/15/06	9/1/10

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2014)			
S0421	Circulating tumor cell (CTC) counts are prognostic of overall survival in SWOG S0421: docetaxel with or without atrasentan for metastatic castration resistant prostate cancer. A Goldkorn, B Ely, DI Quinn, CM Tangen, LM Fink, Tong Xu, P Twardowski, PJ Van Veldhuizen, N Agarwal, M Carducci, JP Monk, RH Datar, M Garzotto, PC Mack, Lara P, Higano CS, M Hussain, IM Thompson, RJ Cote, NJ Vogelzang. <u>Journal of Clinical Oncology</u> , 32(11):1136-1142, 2014. PMID24616308; PMC3970171 http://www.ncbi.nlm.nih.gov/pubmed/24616308	8/21/06	5/1/10
S0421	Serum biomarkers of bone metabolism in castration resistant prostate cancer patients with skeletal metastases. PN Lara, B Ely, DI Quinn, PC Mack, CM Tangen, E Gertz, PW Twardowski, A Goldkorn, M Hussain, NJ Vogelzang, IM Thompson, MD Van Loan. <u>Journal of the National Cancer Institute</u> , 106(4):dju013, 2014. doi: 10.1093/jnci/dju013. PMID24565955; PMC3982883 http://www.ncbi.nlm.nih.gov/pubmed/24565955	8/21/06	5/1/10
S1107	Papillary renal cell carcinoma: current progress and future directions. PW Twardowski, PC Mack, PN Lara, Jr. <u>Clinical Genitourinary Cancer</u> 12(2):74-79, 2014. PMID24629521 (reviews not within scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/24629521	8/20/12	n/a
S1314	Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. C Dinney, D Hansel, D McConkey, W Shipley, M Hagan, R Dreicer, S Lerner, B Czerniak, F Waldman, S Groshen, LD True, E Petricoin, D Theodorescu, A Hruszkewycz, D Bajorin. <u>Urologic Oncology</u> 32(8):1108-15, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25443274	7/9/14	n/a
30904-EORTC	Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. E Scosyrev, EM Messing, R Sylvester, S Campbell, H van Poppe. <u>European Urology</u> 65(2):372-377, 2014. PMID23850254; NIHMS628822 http://www.ncbi.nlm.nih.gov/pubmed/23850254	5/15/00	1/13/03
C90202	Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). MR Smith, S Halabi, CJ Ryan, A Hussain, N Vogelzang, W Stadler, RJ Hauke, JP Monk, P Saylor, N Bhoopalani, F Saad, B Sanford, WK Kelly, M Morris, EJ Small. <u>Journal of Clinical Oncology</u> 32(11):1143-1150, 2014. PMID24590644 PMC3970172. http://www.ncbi.nlm.nih.gov/pubmed/24590644	8/1/04	4/4/12

GU ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2014)

S0925	SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab (IMC-A12) versus androgen deprivation alone for patients with new metastatic castration-sensitive prostate cancer. EY Yu, CM Tangen, CS Higano, N Agarwal, SK Pal, A Alva, EI Heath, ET Lam, S Gupta, MB Lilly, Y Inoue, KN Chi, NJ Vogelzang, DI Quinn, H Li, H Cheng, SR Plymate, MHA Hussain, IM Thompson, Jr. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 5006), 2014. http://abstracts.asco.org/144/AbstView_144_126259.html	12/15/10	12/1/12
S0925	Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. HH Cheng, H Li, CS Higano, CM Tangen, N Agarwal, J Yan, NJ Vogelzang, M Hussain, IM Thompson, Jr., M Tewari, EY Yu. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 5017), 2014. http://abstracts.asco.org/144/AbstView_144_130085.html	12/15/10	12/1/12
S1011	Pre-randomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended vs. standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer. SP Lerner, H Li, R Svatek, T Koppie, A Alva, F La Rosa, R Bangs, S Pal, S Daneshmand, AS Kibel, DJ Canter, CM Tangen, IM Thompson. ASCO Genito-Urinary Cancers Symposium (January 30-February 1, 2014, San Francisco, CA), submitted 10/1/13, poster presentation; <u>Journal of Clinical Oncology</u> 32(suppl 4; abstr 297), 2014. http://meetinglibrary.asco.org/content/124396-142	8/1/11	open
S1216	SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). N Agarwal, C Tangen, M Hussain, P Lara, C Higano, D Vaena, GR MacVicar, H Li, T Crispino, D Quinn, N Vogelzang, I Thompson. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), trials in progress, general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr TPS5102), 2014. http://abstracts.asco.org/144/AbstView_144_130445.html	3/1/13	n/a
S8710	Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort. B Baumann, J He, W-T Hwang, K Tucker, SP Lerner, CM Tangen, H Herr, TJ Guzzo, SB Malkowicz, JP Christodouleas. ASCO Genitourinary Cancers Symposium (January 30-February 1, 2014, San Francisco, CA), poster presentation; <u>Journal of Clinical Oncology</u> 32(suppl 4; abstr 297), 2014. http://meetinglibrary.asco.org/content/124396-142	8/1/87	7/1/98

E2805	Lymphadenectomy at the time of surgery for high risk localized RCC: results from the ASSURE adjuvant trial (ECOG 2805). R Uzzo, J Manola, N Haas, C Kane, C Wood, M Jewett, R DiPaola. American Urological Association 2014 Annual Meeting (May 16 -21, 2014, Orlando, FL), poster discussion; <u>Journal of Urology</u> Vol. 191, No. 4S, Supplement, p. e283 (PD10-04), 2014. http://www.jurology.com/article/S0022-5347(14)00738-1/pdf	5/15/06	9/1/10
E3805	Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. C Sweeney, Y-H Chen, MA Carducci, G Liu, DF Jarrard, MA Eisenberger, Y-N Wong, NM Hahn, M Kohli, NJ Vozelgang, MM Cooney, R Dreicer, J Picus, DH Shevrin, M Hussain, JA Garcia, RS DiPaola. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), accepted, scientific program plenary session (oral). <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr LBA2), 2014 http://abstracts.asco.org/144/AbstView_144_127755.html	9/1/08	11/21/12
R0524	The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. MD Michaelson, C Hu, HT Pham, DM Dahl, C-L Wu, RM Whittington, GP Swanson, J Vuky, RJ Lee, L Souhami, BK Chang, A George, HM Sandler, WU Shipley. American Society of Clinical Oncology Genitourinary Cancers Symposium (January 30 – February 1, 2014, San Francisco CA), oral; <u>Journal of Clinical Oncology</u> 32 (suppl 4; abstr LBA287), 2014. http://meetinglibrary.asco.org/content/123707-142	12/15/06	2/22/13
Multiple Groups*	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. S Halabi, WK Kelly, H Zhou, AJ Armstrong, D Quinn, K Fizazi, NC Solomon, I Tannock, DP Petrylak, MJ Morris, E Small. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 5002), 2014. *includes SWOG S0421 http://abstracts.asco.org/144/AbstView_144_129874.html	n/a	n/a
NONE	Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer- results from the National Cancer Data Base (1998-2011). C Jeldres, K Pham, S Daneshmand, C Kollmannsberger, B Hayes-Lattin, E Wolffe, K Odem-Davis, CR Porter, CR Nichols. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 4519); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlight session.	n/a	n/a

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2013)			
S0353	SWOG S0353: Phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. E Skinner, B Goldman, W Sakr, D Petrylak, H Lenz, CT Lee, S Wilson, M Benson, SP Lerner, CM Tangen, IM Thompson. <i>Journal of Urology</i> 190(4):1200-1204, 2013. PMID23597452; NIHMSID #573393 http://www.ncbi.nlm.nih.gov/pubmed/23597452	11/15/06	10/15/09
S0421	Docetaxel and atrasentan compared docetaxel and placebo for men with advanced castration resistant prostate cancer: SWOG S0421. D Quinn, C Tangen, M Hussain, P Lara, A Goldkorn, M Garzotto, P Mack, M Carducci, JP Monk, P Twardowski, P Van Veldhuizen, N Agarwal, C Higano, N Vogelzang, IM Thompson. <i>Lancet Oncology</i> 14(9):893-900, 2013. PMID23871417 http://www.ncbi.nlm.nih.gov/pubmed/23871417	8/21/06	5/1/10
S9346	Intermittent versus continuous androgen deprivation in prostate cancer. M Hussain, C Tangen, D Berry, C Higano, E Crawford, G Liu, G Wilding, S Prescott, S Kanaga-Sundaram, EJ Small, NA Dawson, B Donnelly, P Venner, U Vaishampayan, PL Schellhammer, DI Quinn, D Raghavan, B Ely, C Moinpour, N Vogelzang, IM Thompson. <i>New England Journal of Medicine</i> , 368(14):1314-1325, 2013. PMID23550669; PMC3682658 http://www.ncbi.nlm.nih.gov/pubmed/23550669	5/15/95	9/1/08
Multiple*	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of an advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. G Sonpavde, GR Pond, R Fougeray, T Choueiri, A Qu, D Vaughn, G Niegisch, P Albers, N James, Y-N Wong, Y-J Ko, S Sridhar, P Galsky, D Petrylak, U Vaishampayan, A Khan, Nicholas Vogelzang, T Beer, W Stadler, P O'Donnell, CN Sternberg, J Rosenberg, J Bellmunt. <i>European Urology</i> , 63(4):717-723, 2013. [Review and analysis of retrospective pooled data]. PMID23206856; (Reviews are not within the scope of the Public Access Policy). *Studies: S0031, S0306 & other (pooled analysis). http://www.ncbi.nlm.nih.gov/pubmed/23206856	n/a	n/a

ABSTRACTS PUBLISHED/PRESENTED (2013)

S8710	Robust risk stratification model predicts local-regional re-currence after radical cystectomy in different patient cohorts. B Baumann, J He, W-T Hwang, K Tucker, S Lerner, C Tangen, H Herr, T Guzzo, SB Malkowicz, J Christodouleas. American Society for Radiation Oncology Annual Meeting (September 22-25, 2013, Atlanta, GA), oral presentation. <u>International Journal of Radiation Oncology * Biology * Physics</u> 87(2):Supplement, p. S82. (selected as one of the abstracts to be presented at the "Best of ASTRO" meeting in San Diego. http://www.redjournal.org/article/S0360-3016(13)00882-1/fulltext	8/1/87	7/1/98
S8710/other (pooled analysis)	Risk stratification for local-regional failure after cystectomy BC Bauman, J He, H Hwang, K Tucker, SP Lerner, CM Tangen, HW Herr, T Guzzo, SB Malkowicz, J Christodouleas. American Urological Association 2013 Annual Meeting (May 4-8, 2013, San Diego, CA), moderated poster discussion, abstr. #1628. http://www.aua2013.org/abstracts/archive/abstracts_Baumann_Brian.cfm	8/1/87	7/1/98

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2012)			
S8494/S8894/ S9346	Improved overall survival trends of men with newly diagnosed M1 prostate cancer: A SWOG phase III trial experience (SS8494, S8894 & S9346). CM Tangen, MHA Hussain, CS Higano, MA Eisenberger, EJ Small, G Wilding, BJ Donnelly, DG McLeod, PF Schellhammer, ED Crawford, NJ Vogelzang, IJ Powell, IM Thompson. <u>Journal of Urology</u> , 188(4):1164-1169, 2012. PMID22921015; PMC3481164 http://www.ncbi.nlm.nih.gov/pubmed/22921015	12/15/89	9/15/94
S9109	Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide prior to radical prostatectomy for clinical T3/T4 prostate cancer: update on Southwest Oncology Group Study 9109. RK Berglund, C Tangen, IJ Powell, BA Lowe, G Haas, P Carroll, ED Canby-Hagino, R deVere White, GP Hemstreet, ED Crawford, IM Thompson, E Klein. <u>Urology</u> 79(3):633-637, 2012. PMID22386416; PMC3839235 http://www.ncbi.nlm.nih.gov/pubmed/22386416	12/1/93	10/15/96
S9450	Prostate cancer – uncertainty and a way forward. IM Thompson, CM Tangen. <u>New England Journal of Medicine</u> 367(3):270-271, 2012. PMID22808963. (Commentary - not within scope of Public Access Policy). http://www.ncbi.nlm.nih.gov/pubmed/22808963	5/1/95	11/30/01
E8802	A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. NB Haas, X Lin, J Manola, M Pins, G Liu, D McDermott, D Nanus, E Heath, G Wilding, J Dutcher. <u>Medical Oncology</u> 29(2):761-767, 2012. PMID21298497; PMC3566570 http://www.ncbi.nlm.nih.gov/pubmed/21298497	5/15/06	4/19/07
EORTC30987	Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Bellmunt, H von der Maase, GM Mead, N Skoneczka, M DeSantis, G Daugaard, J Heyer, L Paz-Ares, L Laufman, E Winquist, D Raghavan, S Marreaud, S Collette, R Sylvester, R de Wit. <u>Journal of Clinical Oncology</u> , 30(10):1107-1113, 2012. PMID22370319; PMC3341152. http://www.ncbi.nlm.nih.gov/pubmed/22370319	6/15/02	6/1/04

NCIC PR7	Intermittent androgen suppression for rising PSA level after radiotherapy. J Crook, CJ O'Callaghan, G Duncan, DP Dearnaley, CS Higano, EM Horwitz, E Frymire, S Malone, J Chin, A Nabid, P Warde, T Corbett, S Angyal, SL Goldenberg, Gospodarowicz, F Saad, JP Logue, E Hall, PF Schellhammer, K Ding, L Klotz. <u>New England Journal of Medicine</u> , 367(10):895-903, 2012. PMID22931259; PMC3521033 http://www.ncbi.nlm.nih.gov/pub_med/22931259	7/1/99	11/30/05
----------	--	--------	----------

ABSTRACTS PUBLISHED/PRESENTED (2012)

S0353	SWOG S0353: Phase II trial of intravesical gemcitabine in patients with superficial bladder cancer with recurrence following 2 prior courses of BCG. E Skinner, B Goldman, W Sakr, P Petrylak, H Lenz, CT Lee, SS Wilson, SP Lerner, CM Tangen, IM Thompson. American Urological Association Annual Meeting (May 19-23, 2012, Atlanta, GA), oral presentation; <u>Journal of Urology</u> 187, No. 4S, Supplement, e673, #1666, 2012. http://download.journals.elsevierhealth.com/pdfs/journals/0022-5347/PIIS0022534712018861.pdf	11/15/06	10/15/09
S0421	SWOG S0421: phase III study of docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer. D Quinn, C Tangen, M Hussain, P Lara, A Goldkorn, M Garzotto, PC Mack, M Carducci, JP Monk, PW Twardowski, PJ Van Veldhuizen, N Agarwal, CS Higano, NJ Vogelzang, IM Thompson. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4511). http://abstract.asco.org/AbstView_114_99398.html	8/21/06	5/1/10
S0421	SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel +/- atrasentan (ATR). PN Lara, B Ely, DI Quinn, C Tangen, E Gertz, M Hussain, NJ Vogelzang, I Thompson, M van Loan. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4547). http://abstract.asco.org/AbstView_114_91416.html	8/21/06	5/1/10
S0421	Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). A Goldkorn, B Ely, DI Quinn, C Tangen, Y-C Tai, PW Twardowski, PJ Van Veldhuizen, N Agarwal, M Carducci, JP Monk, MG Garzotto, PC Mack, PN Lara, CS Higano, M Hussain, N Vogelzang, RJ Cote, IM Thompson. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4663). http://abstract.asco.org/AbstView_114_99398.html	8/21/06	5/1/10

S0421	Results of circulating tumor cell counts using the CellSearch platform in a prospective randomized phase III SWOG-sponsored prostate cancer trial (S0421). N Vogelzang, B Ely, LM Fink, A Goldkorn, CM Tangen, PW Twardowski, PJ Van Velhuizen, N Agarwal, M Carducci, JP Monk, MG Garzotto, PC Mack, PN Lara, CS Higano, M Hussain, DI Quinn, RJ Cote, IM Thompson. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 10503). http://abstract.asco.org/AbstView_114_99469.html	8/21/06	5/1/10
S0421	Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) are prognostic of overall survival (OS) in SWOG S0421 – docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). A Goldkorn, NJ Vogelzang, B Ely, LM Fink, DI Quinn, CM Tangen, Y-C Tai, P Twardowski, PJ Van Veldhuizen, N Agarwal, MA Carducci, JP Monk, M Garzotto, PC Mack, P Lara, CS Higano, M Hussain, RJ Cote, IM Thompson. ASCO Markers in Cancer Annual Meeting (October 11-13, 2012, Hollywood, FL), oral presentation; <u>J Clin Oncol</u> 30: 2012 (suppl 30; abstr 1). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=127&abstractID=103697	8/21/06	5/1/10
S9346	Intermittent (IAD) vs continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162) an international phase III trial. M Hussain, C Tangen, C Higano, E Crawford, G Liu, G Wilding, S Prescott, A Akdas, E Small, N Dawson, B Donnelly, P Venner, U Vaishampayan, P Schellhammer, D Quinn, D Raghavan, N Vogelzang, IM Thompson. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation (plenary session); <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4). http://abstract.asco.org/AbstView_114_92516.html	5/15/95	9/1/08
S9346	Preliminary quality of life outcomes for SWOG-9346: intermittent androgen deprivation in patients with hormone sensitive metastatic prostate cancer (HSM1PC), phase III. C Moinpour, DL Berry, B Ely, C Tangen, C Higano, J Picus, P Schellhammer, C Skinner, M Cher, I Thompson, M Hussain. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>Journal of Clinical Oncology</u> 30, 2012 (suppl; abstr 4571). http://abstract.asco.org/AbstView_114_101068.html	5/15/95	9/1/08
E2805	Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). NB Haas, J Manola, B Ky, KT Flaherty, RG Uzzo, CG Wood, CJ Kane, MAS Jewett, MB Atkins, JP Dutcher, RS DiPaola. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>Journal of Clinical Oncology</u> 30(suppl; abstr 4500), 2012. http://meetinglibrary.asco.org/content/94335-114	5/15/06	9/1/10

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2011
(PCPT and SELECT listed with CC&P Committees)**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2011)			
S0032	Phase II evaluation of early oral estramustine, oral etoposide and intravenous paclitaxel in combination with hormone therapy in patients with high risk metastatic adenocarcinoma of the prostate: Southwest Oncology Group (SWOG) S0032. DC Smith, DM Tangen,, PJ Van Veldhuizen, GW Harrer, A Golshayan, GM Mills, NJ Vogelzang, IM Thompson, MHA Hussain. <u>Urology</u> 77(5):1172-1176, 2011; PMID21334731; PMC3528346 http://www.ncbi.nlm.nih.gov/pubmed/21334731	12/1/01	6/1/05
S8710	Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer treated with radical cystectomy? A secondary analysis of Southwest Oncology Group-directed intergroup Study (S8710). E Scosyrev, BW Ely, EM Messing, VO Speights, HB Grossman, DP Wood, RW de Vere White, NJ Vogelzang, DL Trump, R Natale, C Tangen, ED Crawford, IM Thompson. <u>British Journal of Urology International</u> 108(5):693-699, 2011; PMID21105991; PMC3117124 http://www.ncbi.nlm.nih.gov/pubmed/21105991	8/1/87	7/1/98
S9917	Selenium supplementation and prostate cancer among men with high grade prostatic intraepithelial neoplasia: SWOG-directed intergroup trial S9917. JR Marshall, CM Tangen, WA Sakr, DP Wood, DL Berry, EA Klein, SM Lippman, HL Parnes, DS Alberts, DF Jarrard, WR Lee, JM Gaziano, ED Crawford, B Ely, M Ray, W Davis, L Minasian, IM Thompson. <u>Cancer Prevention Research</u> , 4(11):1761-1769, 2011. PMID21896650; PMC3208719 http://www.ncbi.nlm.nih.gov/pubmed/21896650	2/1/00	11/1/06
S9921	Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. T Dorff, T Flaig, C Tangen, M Hussain, G Swanson, DP Wood, W Sakr, N Dawson, N Haas, ED Crawford, NJ Vogelzang, IM Thompson, LM Glode. <u>Journal of Clinical Oncology</u> , 29(15):2040-2045, 2011. PMID21502546; PMC3107759 http://www.ncbi.nlm.nih.gov/pubmed?term=dorff%20t%20S9921	10/15/99	1/12/07

4B951	A phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. W Stadler, SP Lerner, S Groshen, JP Stein, E Tuazon, D Skinner, D Raghavan, D Esrig, G Steinberg, D Wood, L Klotz, C Hall, R Cote. <u>Journal of Clinical Oncology</u> , 29(25):3443-9, 2011. PMID21810677; PMC3164246 http://www.ncbi.nlm.nih.gov/pubmed/21810677	10/15/01	3/28/06
-------	--	----------	---------

JPR3 (NCIC-CTG)	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomized, phase 3 trial. P Warde, M Mason, K Ding, P Kirkbride, M Brundage, R Cowan, M Gospodarowicz, E Kostashuk, G Swanson, J Barber, A Hiltz, MK Parmer, J Sathya, J Anderson, J Hetherington, MR Sydes, W Parulekar. <u>Lancet</u> 378(9809):2104-2111, 2011. PMID 22056152; PMC3243932 http://www.ncbi.nlm.nih.gov/pubmed/22056152	11/106	8/31/05
--------------------	--	--------	---------

GU ABSTRACTS PUBLISHED/PRESENTED (2011)

S0931	SWOG 0931 – Everest: EVErolimus for renal cancer ensuing surgical therapy, a phase II study. CW Ryan, CM Tangen, EI Heath, PN Lara, GS Palapattu, PC Mack, MN Stein, BW Ely, IM Thompson. 10 th International Kidney Cancer Symposium (Oct 14-15, 2011, Chicago, IL), poster presentation.	4/1/11	n/a
-------	---	--------	-----

JPR.7 (NCIC-CTG)	A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU J PR.7/UK intercontinental trial CRUKE/01/013. JM Crook, CJ O'Callaghan, K Ding, G Duncan, D Dearnaley, C Higano, E Horwitz, E Frymire, S Malone, J Chin, A Nabid, P Warde, T Corbett, S Angyalfi, SL Goldenberg, MK Gospodarowicz, J Loque, P Schellhammer, F Saad, L Klotz. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), oral presentation; <u>Journal of Clinical Oncology</u> 29: (suppl; abstr 4514), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775	7/1/99	11/30/05
---------------------	---	--------	----------

JPR.7 (NCIC-CTG)	A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK intercontinental trial CRUKE/01/013. L Klotz, CJ O'Callaghan, K Ding, D Dearnaley, CS Higano, EM Horwitz, S Malone, SL Goldenberg, MK Gospodarowicz, JM Crook. ASCO GU Symposium (poster presentation. <u>Journal of Clinical Oncology</u> 29:2011 (suppl 7; abstr 3). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=104&abstractID=72503	7/1/99	11/30/05
---------------------	--	--------	----------

**SWOG
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2010
(PCPT and SELECT publication listed CCP Committees)**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2010)			
S0031	Results of Southwest Oncology Group phase II evaluation (study S0031) of ZD 1839 for Advanced transitional cell carcinoma of the urothelium. DP Petrylak, C Tangen, PJ VanVeldhuizen, W Goodwin, PW Twardlowski, JN Atkins, SR Dakhil, ML Lange, ED Crawford. <u>British Journal of Urology</u> , 105(3):317-321, 2010. PMID: 19888985 http://www.ncbi.nlm.nih.gov/pubmed/19888985	2/15/01	10/15/02
S0354	Clinical and correlative results of SWOG S0354: a Phase II trial of CNT0328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pre-treated patients with castration-resistant Prostate cancer (CRPC). T Dorff, B Goldman, J Pinski, P Mack, P Lara, P Van Veldhuizen, DI Quinn, N Vogelzang, IM Thompson, M Hussain. <u>Clinical Cancer Research</u> , 16(11):3028-3034, 2010. PMC2898710; PMID20484019 http://www.ncbi.nlm.nih.gov/pubmed?term=dorff%20t%20monoclonal	4/1/07	5/15/08
GU ABSTRACTS PUBLISHED/PRESENTED (2010)			
S0028	Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced (adv) urothelial cancer (UC), aged $\geq$ 70 years (yrs): SWOG 0028. D Raghavan, C Tangen, C Moinpour, C Gotay, K Albain, S Louie, H-J Lenz, D Quinn, M Hussain, I Thompson. Poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s (suppl; abstr 4569), 2010 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51619	7/1/01	12/15/06
S0421	Circulating tumor cell capture and analysis in a multi-center SWOG-coordinated prostate cancer trial. A Goldkorn, T Xu, B Lu, A Williams, LM Fink, CM Tangen, Y-C Tai, DI Quinn, P Twardowski, RJ Cote. "Trials in Progress" poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s (suppl;abstr TPS342), 2010 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53487	8/21/06	n/a

S8710	Do Mixed Histologic Features Affect Survival Benefit from Neo-Adjuvant Platinum-Based Combination Chemotherapy In Patients With Locally Advanced Bladder Cancer? E Scosyrev, BW Ely, EM Messing, VO Speights, HB Grossman, DP Wood, RW deVereWhite, NJ Vogelzang, DL Trump, RB Natale, C Tangen, ED Crawford, IM Thompson. Poster presentation, 2010 Annual Meeting of the American Urological Association; <u>Journal of Urology</u> 183(4):suppl. E659 (abstr #1708), 2010. http://www.jurology.com/article/S0022-5347(10)01811-2/fulltext	8/1/87	7/1/98
*S8710	Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? Messing EM, Scosyrev E, Grossman HB, deVereWhite R, Trump DL, Natale RB, Tangen C, Crawford ED, Thompson IM. Oral Presentation, 2010 American Society for Clinical Oncology Genitourinary Cancers Symposium (March 5-7, 2010, San Francisco, CA), abstr. # 274. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30750	8/1/87	7/1/98
S9346/S8894	Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (PCa): better efficacy or stage migration? Data from SWOG:S9346 and 8894. M Hussain, CM Tangen, CS Higano, MA Eisenberger, EJ Small, G Wilding, BJ Donnelly, D McLeod, ED Crawford, IM Thompson. Poster presentation, 2010 American Society for Clinical Oncology Genitourinary Cancers Symposium, abstr. 30, 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30449	n/a	n/a
S9917	Southwest Oncology Group (SWOG) trial S9917: Randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia (HGPIN). JR Marshall, CM Tangen, WA Sakr, DP Wood, SM Lippman, D Jarrad, DS Alberts, DL Berry, ED Crawford, IM Thompson. American Urological Association 2010 Annual Meeting, "late breaking" oral presentation.	2/1/00	11/1/06
S9921	Southwest Oncology Group study 9921: prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. IM Thompson, CM Tangen, MHA Hussain, DP Wood, GP Swanson, DI Quinn, TB Dorff, NA Dawson, NB Haas, ED Crawford, LM Glode. Oral presentation, American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA), "late breaking" abstract .	10/15/99	01/12/08
*JPR3	Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CAP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). PR Warde, MD Mason, MR Sydes, MK Gospodarowicz, GP Swanson, P Kirkbride, E Kostashuk, J Hetherington, K Ding, W Parulekar, NCIC CTG PR.3/MRC PRO7/ SWOG JPR3 investigators. Oral presentation, American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); <u>Journal of Clinical Oncology</u> 28:7s, (suppl; abstr CRA4504), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49170	11/1/96	8/31/05

4B951	Cell cycle regulatory protein alterations in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. S Lerner, W Stadler, S Groshen, J Cai, A Mitra, E Tuazon, D Skinner, D Raghavan, D Esrig, G Steinberg, C Hall, R Cote. Poster presentation, American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA); <u>Journal of Urology</u> 183(4);suppl.E662 (abstr 1715), 2010. http://www.jurology.com/article/S0022-5347(10)01818-5/fulltext	10/15/01	3/28/06
-------	--	----------	---------

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GENITOURINARY COMMITTEE
2009
(PCPT and SELECT publications are listed separately)**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GU MANUSCRIPTS PUBLISHED (2009)			
S8507 (2379)	Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer. SP Lerner, CM Tangen, H Sucharew, D Wood, ED Crawford. <u>Urologic Oncology</u> 27(2):155-159, 2009. PMID: 18367117	12/20/85	12/15/88
S8710 (2624)	Quality of pathologic response and surgery correlate with survival for completely resected bladder cancer following neoadjuvant mVAC. G Sonpavde, BH Goldman, VO Speights, SP Lerner, DP Wood, NJ Vogelzang, DL Trump, RB Natale, HB Grossman, ED Crawford. Not accepted by <u>JNCI</u> 11/08; <u>Cancer</u> , 12115(18):4104-4109, 2009. PMID: 19517476	8/1/87	7/1/98
S8794 (2613)	Adjuvant radiotherapy for pathological T3N0M0 prostate Cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. IM Thompson, CM Tangen, J Paradelo, MS Lucia, G Miller, D Troyer, E Messing, J Forman, J Chin, G Swanson, E Canby-Hagino and ED Crawford. <u>Journal of Urology</u> , 181(3):956-962, 2009. PMID: 19167731	8/15/88	1/1/97
S8949 (2561)	Predictors of survival in advanced renal cell carcinoma: long-term results from Southwest Oncology Group trial S8949. PN Lara, CM Tangen, S Conlon, RC Flanigan, ED Crawford. Submitted to JU 2008; <u>Journal of Urology</u> , 181(2) 512-516, 2009. PMID: 19100570	3/1/94	8/1/00
S9346/9916 (2584)	Prostate-specific antigen progression (PSA-P) predicts overall survival (OS) in patients with metastatic prostate cancer: data from Southwest Oncology Group (SWOG) Trials 9346 (INT 0162) and 9916. M Hussain, B Goldman, C Tangen, C Higano, DP Petrylak, G Wilding, A Akdas, EJ Small, BJ Donnelly, L Collette, PA Burch, RS DiPaola, ED Crawford. <u>Journal of Clinical Oncology</u> 27(15):2450-2456, 2009. PMID: 19380444	5/15/95 10/15/99	9/1/08 1/15/03
S9916 (2559)	Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: dynamically modified outcomes analysis of a randomized controlled trial. CM Moinpour, GW Donaldson, Y Nakamura. <u>Quality of Life Research</u> 18:147-155, 2009. PMID: 19130298	10/15/99	1/15/03
S9921	Biased hormonal therapy analysis makes results uninterpretable. CM Tangen, B Goldman, G Swanson, IM Thompson. In press, <u>Journal of Clinical Oncology</u> , 27(33): e203, 2009. PMID: 19786655	10/15/99	01/12/08

S0031 (2580)	Results of Southwest Oncology Group phase II evaluation (study S0031) of ZD 1839 for Advanced transitional cell carcinoma of the urothelium. DP Petrylak, C Tangen, PJ VanVeldhuizen, W Goodwin, PW Twardlowski, JN Atkins, SR Dakhil, ML Lange, ED Crawford. <u>British Journal of Urology</u> , 2009 Nov 2 [Epub ahead of print]. PMID: 19888985	2/15/01	10/15/02
S0219 (2591)	A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group Trial (S0219). RW de Vere White, PN Lara, B Goldman, MC Tangen, DC Smith, DP Wood, MHA Hussain, ED Crawford. <u>Journal of Urology</u> 181(6): 2476-2480, 2009. PMID:1937909	1/1/03	12/15/06
S0312 (2560)	A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer (RCC): Southwest Oncology Group study S0312. PJ Van Veldhuizen, M Hussey, PN Lara, PC Mack, R Gandour-Edwards, JI Clark, MK Lange, ED Crawford. <u>American Journal of Clinical Oncology</u> , 2009 May 29 [Epub ahead of print] PMID: 19487915	12/1/04	8/15/05
S0317 (2563)	A phase II study of erlotinib (OSI-774) in patients with locally advanced or metastatic papillary histology renal cell cancer SWOG S0317. MS Gordon, M Hussey, R Nagle, PN Lara, Jr, PC Mack, J Dutcher, W Samlowski, JI Clark, DI Quinn, CX Pan, DE Crawford. <u>Journal of Clinical Oncology</u> 27(34):5788-5793, 2009. PMID: 19884559	5/1/03	12/15/05
Multiple (2686)	Cooperative group trials – Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. TB Dorff, CM Tangen, ED Crawford, DP Petrylak, CS Higano, D Raghavan, DI Quinn, NJ Vogelzang, IM Thompson, MHA Hussain. <u>Therapeutic Advances in Medical Oncology</u> , 1(2):69-77, 2009.	n/a	n/a

GU MANUSCRIPTS SUBMITTED/ACCEPTED (2009)

S8710	Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer treated with radical cystectomy? A secondary analysis of Southwest Oncology Group-directed intergroup Study (S8710). E. Scosyrev, B.W. Ely, E.M. Messing, V.O. Speights, H. B. Grossman, D.P. Wood, R.W. de Vere White, N.J. Vogelzang, D.L.Trump, R.B. Natale, C. Tangen, E.D. Crawford, I.M.Thompson. Submitted to <u>Journal of Clinical Oncology</u> , 9/09.	8/1/87	7/1/98
S9109	Long-term follow-up of neoadjuvant therapy prior to radical prostatectomy for clinical T3/T4 prostate cancer: a Southwest Oncology Group Study 9109. IM Thompson, IJ Powell, BA Lowe, G Haas, P Carroll, ED Canby-Hagino, R deVere White, GP Hemstreet, ED Crawford. Resubmitted to <u>Journal of Urology</u> , 10/13/09.	12/1/93	10/15/96

S9142 (1697)	Phase II study of continuous infusion gallium nitrate in platinum-refractory urothelial tract tumors: a Southwest Oncology Group Study. DP Petrylak, E Fisher, PA Seligman, HM Gross, D Raghavan, AJ Bueschen, PF Schellhammer, SS Buys, ED Crawford. Not accepted by <u>Cancer</u> , 10/31/02; submitted to <u>Urology</u> , 2/10/09; revisions submitted, pending acceptance 12/09	9/15/93	2/1/96
-----------------	--	---------	--------

GU ABSTRACTS PUBLISHED/PRESENTED (2009)

S8710 (2601)	Quality of pathologic response and surgery correlate with survival for completely resected bladder cancer following neoadjuvant MVAC. G Sonpavde, BH Goldman, VO Speights, SP Lerner, DP Wood, NJ Vogelzang, DL Trump, RB Natale, HB Grossman, ED Crawford. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, abst.#249.	8/1/87	7/1/98
*S8794	Lack of low-risk pathologic findings in SWOG 8794. G Swanson, B Goldman, C Tangen, IM Thompson, J Chin, E Mesing, E Canby-Higano, JD Forman, E Crawford. <u>International Journal of Radiation Oncology, Biology & Physics</u> 75(S):abst. #20, S10, 2009 (ASTRO,oral presentation).	8/15/88	1/1/97
S9217	Cancer prevention clinical trials: assessing for disparities in recruitment in Hawaii. E. Bantum, I Cheng, K Cassel, L Ka'opua, J Berenberg. Poster Presentation, American Association of Cancer Research 2009; Proceedings of Frontiers in Cancer Prevention Research, abst. #B26, p. 116, 2009.	10/13/93	12/6/96
*S9921 (2639)	Southwest Oncology Group S9921: prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. LM Glode, CM Tangen, MHA Hussain, DP Wood, GP Swanson, N Dawson, N Balzer-Haas, DI Quinn, E David Crawford, IM Thompson. <u>Journal of Clinical Oncology</u> 27:15s, abst. #5009, 2009.	10/15/99	open
S0354 (2632)	SWOG S0354: a phase II trial of CNT0328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pre-treated patients (pts) with castration resistant prostate cancer (CRPC). J Pinski, B Goldman, T Dorff, P Mack, P Lara, P vanVeldhuizen, D Quinn, MHA Hussain, IM Thompson. <u>Journal of Clinical Oncology</u> 27:15s, abst. #5143, 2009.	4/1/07	5/15/08
4B951 (2610)	Variability in surgical quality in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. SP Lerner, JP Stein, WM Stadler, S Groshen, E Tuazon, DG Skinner, D Raghavan, D Esrig, G Steinberg, L Klotz, C Hall, R Cote. Poster presentation, American Urological Association Annual Meeting, 2009, abstract #1747.	10/15/01	3/28/06

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GU COMMITTEE
2008**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
GU MANUSCRIPTS PUBLISHED/PRESENTED				
8733 (2408)	Treatment options for muscle invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin: report of Southwest Oncology Group trial 8733. CS Higano, CM Tangen, WA Sakr, KJ Russell, J Faulkner, SE Rivkin, FJ Meyers, M Hussain, LH Baker, EJ Russell, D Raghavan, ED Crawford. <u>Cancer</u> , 112(10):2181-2187, 2008. PMID 18404692	GU	4/1/88	2/15/97
8794 (2481)	The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation in those patients: data from SWOG 8794. GP Swanson, B Goldman, CM Tangen, JL Chin, EM Messing, ED Canby-Higino, JD Forman, IM Thompson, ED Crawford. Accepted by the <u>Journal of Urology</u> , 180:2453-2457, 2008. PMID: 18930488	GU	8/15/88	1/1/97
8994 (2301)	Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. CM Moynour, KA Hayden, JM Unger, IM Thompson Jr, MW Redman, ED Canby-Hagino, BA Higgins, JW Sullivan, D Lemmon, S Breslin, ED Crawford. <u>Journal of Clinical Oncology</u> 26(1):112-120, 2008. PMID: 18165645	CC GU	2/15/90	1/1/97
9217 (2471)	Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia. ML Neuhouwer, J Schenk, Y Song, CM Tangen, P Goodman, M Pollak, DF Penson, IM Thompson, AR Kristal. <u>Prostate</u> 68(13):1477-1486, 2008. PMID: 18618736	GU CC	10/13/93	12/6/96
9217 (2456)	Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Y Song, C Tangen P Goodman, HL Parnes, MS Lucia, IM Thompson, AR Kristal. <u>The Prostate</u> 68:281-286, 2008. PMID: 18163420	GU CC	10/13/93	12/6/96
9217 (2467)	The performance of PSA for predicting prostate cancer is maintained after a prior negative prostate biopsy. IM Thompson, CM Tangen, DP Ankerst, C Chi, MS Lucia, P Goodman, HL Parnes, CA Coltman. <u>Journal of Urology</u> 180(2):544-547, 2008. PMID: 18550097	GU CC	10/13/93	12/6/96
9217 (2457)	Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial. A Hoque, P. Goodman, CB Ambrosone, WD Figg, DK Price, W Kopp, X Wu, J Conroy, TA Lehman, RM Santella. <u>Urology</u> 71(5):967-970, 2008. PMID: 18267333 .	GU CC	10/13/93	12/6/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9217 (2396)	Dietary patterns, supplement use and the risk of symptomatic benign prostatic hyperplasia (BPH): results from the Prostate Cancer Prevention Trial. AR Kristal, KB Arnold, JM Schenk, ML Neuhouser, P Goodman, DF Penson, IM Thompson. <u>American Journal of Epidemiology</u> 167(8):925-934, 2008. PMID: 1823602	GU CC	10/13/93	12/6/96
9217 2473	Integrating the predictiveness of a marker with its performance as a classifier. MS Pepe, Z Feng, Y Huang, G Longton, R Prentice, IM Thompson, Y Zheng. <u>American Journal of Epidemiology</u> . 167(3)362-368, 2008. PMID: 179821157	GU CC	10/13/93	12/6/96
9217 (2492)	Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. MS Lucia, A Darke, PJ Goodman, FG LaRosa, HL Parnes, LG Ford, CA Coltman, Jr., IM Thompson. <u>Cancer Prevention Research</u> 1(3):167-173, 2008. PMID: 19138952	GU CC	10/13/93	12/6/96
9217 (2433)	Does the level of prostate cancer risk affect cancer prevention with finasteride? IM Thompson, CM Tangen, HL Parnes, SM Lippman, CA Coltman Jr. <u>Urology</u> 71(5); 854-857, 2008. PMID: 18455628	GU CC	10/13/93	12/6/96
9217 (2467)	The performance of PSA for predicting prostate cancer is maintained after a prior negative prostate biopsy. IM Thompson, CM Tangen, DP Ankerst, C Chen, MS Lucia, P Goodman, HL Parnes, CA Coltman. <u>Journal of Urology</u> . 180(2):544-547, 2008. PMID: 18550097	GU CC	10/13/93	12/6/96
9217 (2470)	Serum steroid and sex hormone binding globulin concentrations and the risk of incident benign prostatic hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. AR Kristal, Y Song, JM Schenk, KB Arnold, ML Neuhouser, P Goodman, CM Tangen, DW Lin, FZ Stanczyk, and IM Thompson. <u>American Journal of Epidemiology</u> . 168(12):1416-1424, 2008. PMID: 18945688	GU CC	10/13/93	12/6/96
9217 (2493)	Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. MW Redman, CM Tangen, PJ Goodman, MS Lucia, CA Coltman, IM Thompson. <u>Cancer Prevention Research</u> 1(3):174-181, 2008. PMID: 19138953	GU CC	10/13/93	12/6/96
9217 (2433)	Does the level of prostate cancer risk affect cancer prevention with finasteride? IM Thompson, CM Tangen, HL Parnes, SM Lippman, CA Coltman Jr. <u>Urology</u> . 71(5):854-857, 2008. PMID: 18455628	GU CC	10/13/93	12/6/96
9217 (2480)	Does finasteride affect the severity of prostate cancer? A causal sensitivity analysis. BE Shepherd, MW Redman, DP Ankerst. Accepted by <u>Journal of the American Statistical Association</u> , 103(484):1392-1404, 2008. (PMID number not available).	GU CC	10/13/93	12/6/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9426 (2336)	Antiandrogen withdrawal in hormone refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). AO Sartor, CM Tangen, MHA Hussain, MA Eisenberger, M Parab, JA Fontana, RA Chapman, GM Mills, D Raghavan, ED Crawford. <u>Cancer</u> 112(11):2392-2400, 2008. PMID 1838357	GU	3/15/95	06/01/01
9460 (2428)	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. AL Sabichi, SP Lerner, EN Atkinson, HB Grossman, NP Caraway, CP Dinney, DF Penson, S Matin, A Kamat, LL Pisters, DW Lin, RL Katz, DE Brenner, GP Hemstreet III, M Wargo, A Bleyer, WH Sanders, JL Clifford, HL Parnes, SM Lippman. <u>Clinical Cancer Research</u> 14(1):224-229, 2008. PMID: 18172274	GU CC	6/1/96	10/15/99
S9921 (2392)	Randomization reveals unexpected acute leukemias in SWOG prostate cancer trial. TW Flaig, CM Tangen, MHA Hussain, WM Stadler, D Raghavan, ED Crawford, LM Glode. <u>Journal of Clinical Oncology</u> 26(9):1532-1536, 2008. PMID: 18349405	GU	10/15/99	01/12/08
S0306 (2431)	Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium. TM Beer, B Goldman, CR Nichols, DP Petrylak, M Agarwal, CW Ryan, ED Crawford. <u>Clinical Genitourinary Cancer</u> 6(1):36-39, 2008. PMID:18501081	GU	7/15/03	2/1/07
S0418 (2587)	Southwest Oncology Group phase II study of Ispinesib in androgen-independent prostate cancer (AIPC) previously treated with taxanes. TM Beer, B Goldman, TW Synold, CW Ryan, LS Vasist, PJ Van Veldhuizen, Jr, SP Dakhil, JP Lara, A Drelichman, MHA Hussain, ED Crawford. <u>Clinical Genitourinary Cancer</u> 6(2):103-109, 2008. PMID18824433	4/1/05	5/1/06	

GU ABSTRACTS PUBLISHED/PRESENTED

*S8794 (2528)	Adjuvant radiotherapy for pT3 for prostate cancer: results of a randomized, prospective clinical trial, 2008 update. GP Swanson, IM Thompson, C Tangen, J Paradelo, E Canby-Hagino, ED Crawford, F Miller, MS Lucia, J Forman, J Chin E Messing. Presented ("late breaking") at <u>American Urological Association Annual Meeting</u> , 2008.	8/15/88	1/1/97	
*S8794 (2614)	Updated results of SWOG 8794: adjuvant radiation for high risk prostate cancer. G Swanson, I Thompson, C Tangen, J Pardelo, E Canby-Hagino, E Crawford, G Miller, M Lucia, J Forman, J Chin, E Messing. ESTRO 27, Goteborg, Sweden, September, 2008; <u>Radiotherapy and Oncology</u> 88(S2):S148(449), 2008. http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf	8/15/88	1/1/97	

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S8794 (2615)	Prognostic significance of pathologic SV Involvement and the effect of adjuvant radiation therapy on outcome. I Thompson, B Goldman, C Tangen, J G Swanson, Chin, E Messing, E Canby-Hagino, J Forman, E Crawford. ESTRO 27, Goteborg, Sweden, September, 2008; <u>Radiotherapy and Oncology</u> 88(S2):S337(1057), 2008. http://www.estro27.org/programme/Documents/ESTRO27%20AbstractBook.pdf	8/15/88	1/1/97	
*S8794 (2616)	Update of SWOG 8794: Adjuvant radiotherapy for pT3 Prostate cancer improves metastasis free survival. G Swanson, IM Thompson, C Tangen, J Paradelo, E Canby-Hagino, E Crawford, G Miller, MS Lucia, J Forman, J Chin. ASTRO, Boston, MA, September, 2008; <u>International Journal of Radiation Oncology Biology Physics</u> , 72(1) suppl. 1:S31, 2008 http://www.sciencedirect.com.libproxy.uthscsa.edu/science?_ob=ArticleURL&_udi=B6T7X-4T85W5M-2R&_user=108488&_coverDate=09%2F01%2F2008&_alid=785532217&_rdoc=1&_fmt=high&_orig=search&_cdi=5070&_sort=d&_docanchor=&view=c&_ct=29&_acct=C000059724&_version=1&_urlVersion=0&_userid=108488&md5=5cae9b1302e5a1e06e12146c78d74ea0	8/15/88	1/1/97	
**S8949 (2509)	Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949. S Conlon, CM Tangen, RC Flanigan, ED Crawford, PN Lara. <u>Journal of Clinical Oncology</u> 26(15S):260s, #5042, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32157	3/1/94	8/1/00	
*S8949 (2661)	Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949. S Conlon, CM Tangen, RC Flanigan, ED Crawford, PN Lara. <u>American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium</u> , abstract #347. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20243	3/1/91	10/1/98	
*S9346/S9916 (2511)	Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. M Hussain, B Goldman, C Tangen, C Higano, DP Petrylak, ED Crawford. <u>Journal of Clinical Oncology</u> 26(15S):253s, #5015, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32059	n/a	n/a	
***9346/S9916 (2524)	Prostate-specific antigen progression (PSA-P) as a predictor of overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. B Goldman, M Hussain, C Tangen, C Higano, DP Petrylak, NJ Vogelzang, ED Crawford. <u>American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium</u> , abstract #165. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20310	n/a	n/a	

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S0219 (2514)	A sequential treatment approach to muscle-invasive urothelial cancer – a phase II Southwest Oncology Group trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG). PN Lara Jr, B Goldman, R deVere White, C Tangen, DC Smith, D Wood, M Hussain, ED Crawford. <u>Journal of Clinical Oncology</u> , 26(15S):255s, #5022, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32346	1/1/03	12/15/06	
**S0317 (2440)	Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317. C Pan, M Hussey, P Lara, P Mack, R Nagle, J Dutcher, W Samlowski, J Clark, M Gordon, E Crawford. <u>Journal of Clinical Oncology</u> , 26(15S):262s, #5051, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31466	5/1/03	12/15/05	
*4B951 (2609)	Results of the p53 targeted therapy trial for patients with organ confined node negative bladder cancer treated with radical cystectomy. SP Lerner, JP Stein, WM Stadler, S Groshen, E Tuazon, DG Skinner, D Raghavan, D Esrig, G Steinberg, C Hall, R Cote. Oral presentation at 2008 Annual Meeting of the Society of Urological Oncology (December).	10/15/01	3/28/06	

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8507 (2370)	Patterns of recurrence and outcomes following induction bacillus calmette-guerin for high risk Ta, T1 bladder cancer. SP Lerner, CM Tangen, H Sucharew, D Wood, ED Crawford. <u>Journal of Urology</u> 177:1727-1731, 2007.	GU	12/20/85	12/15/88
8794 (2364)	Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. GP Swanson, MA Hussey, CM Tangen, J Chin, E Messing, E Canby-Hagino, JD Foreman, IM Thompson, ED Crawford. <u>Journal of Clinical Oncology</u> 25(16):2225-2229, 2007.	GU	8/15/88	1/1/97
8894/9916 (2366)	Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. RB Montgomery, B Goldman, CM Tangen, M Hussain, DP Petrylak, S Page, EA Klein, ED Crawford. <u>Journal of Clinical Oncology</u> , 178(5):1946-1951, 2007. PMID: 17868721	GU		
9217 (2371)	Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. IM Thompson, CM Tangen, PJ Goodman, MS Lucia, HL Parnes, SM Lippman, CA Coltman, Jr. <u>Journal of Urology</u> 177:1749-1752, 2007.	GU CC	10/13/93	12/6/96
9217 (2302)	Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. CM Moinpour, AK Darke, GW Donaldson, IM Thompson, Jr, C Langley, DP Ankerst, DL Patrick, JE Ware, Jr, PA Ganz, SA Shumaker, SM Lippman, CA Coltman, Jr. <u>Journal of the National Cancer Institute</u> 99:1025-1035, 2007.	GU CC	10/13/93	12/6/96
9217 (2393)	Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. AR Kristal, KB Arnold, JM Schenk, ML Neuhaus, N Weiss, P Goodman, CM Antvelink, DF Penson, IM Thompson. <u>Journal of Urology</u> 177:1395-1400, 2007.	GU CC	10/13/93	12/6/96
9217 (2376)	Finasteride decreases the risk of prostatic intraepithelial neoplasia. IM Thompson, SM Lucia, MW Redman, A Darke, FG La Rosa, HL Parnes, SM Lippman, CA Coltman. <u>Journal of Urology</u> 178:107-110, 2007.	GU CC	10/13/93	12/6/96
9217 (2395)	Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. IM Thompson, DP Ankerst, C Chi, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr. <u>Journal of Clinical Oncology</u> 25(21): 3076-3081, 2007.	GU CC	10/13/93	12/6/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9217 (2369)	Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. MS Lucia, JI Epstein, PJ Goodman, AK Darke, VE Reuter, F Civantos, CM Tangen, HL Parnes, SM Lippman, F La Rosa, MW Kattan, ED Crawford, LG Ford, CA Coltman Jr, IM Thompson. <u>Journal of the National Cancer Institute</u> 99(18):1375-1383, 2007. PMID: 17848673	GU CC	10/13/93	12/6/96
9217 (2472)	Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. Etzioni RD. Ankerst DP. Weiss NS. Inoue LY. Thompson IM. <u>Journal of the National Cancer Institute</u> 99(20):1510-5, 2007. PMID: 17925534	GU CC	10/13/93	12/6/96
S9809 (2340)	Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. SR Wolman, B Goldman, ML Slovak, C Tangen, DL Persons, D Wood. <u>Cancer Genetics and Cytogenetics</u> 176:22-27, 2007.	GU	4/15/99	7/1/01
S9916 2389	Do general dimensions of quality of life add clinical value to symptom data? CM Moynour, GW Donaldson, Redman MW. <u>Journal of the National Cancer Institute</u> 37:31-38, 2007. PMID: 17951229	GU	10/15/99	1/15/03
S0412 (2373)	Sorafenib with interferon alpha-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. CW Ryan, BH Goldman, PN Lara Jr, PC Mack, TM Beer, CM Tangen, D Lemmon, CX Pan, HA Drabkin, ED Crawford. <u>Journal of Clinical Oncology</u> 25(22):3296-3301, 2007.	GU	9/1/04	5/15/05
ABSTRACTS PUBLISHED/PRESENTED				
S0312 (2347)	A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): results of Southwest Oncology Group study 0312. PJ Van Veldhuizen Jr, M Hussey, PN Lara, PH Gumerlock, J Clark, MK Lange, ED Crawford. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#15562, 2007.	GU	12/1/04	8/15/05
S0317 (2348)	Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)--SWOG S0317. C Pan, M Hussey, P Lara, PC Mack, RB Nagle, J Dutcher, W Samlowski, J Clark, ED Crawford, MS Gordon. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#15516, 2007.	GU	5/01/03	12/15/05
S0412 (2351)	Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): an analysis of SWOG 0412. BH Goldman, PN Lara, Jr, TM Beer, PC Mack, HA Drabkin, WS Holland, ED Crawford, CW Ryan. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#5108, 2007.	GU	9/01/04	5/15/05

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8794 (2268)	Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. IM Thompson Jr., CM Tangen, J Paradelo, MS Lucia, G Miller, D Troyer, E Messing, J Forman, J Chin, G Swanson, E Canby-Hagino, ED Crawford. <u>Journal of the American Medical Association</u> 296(19):2329-2335, 2006.	GU	8/15/88	1/1/97
8894 (2262)	The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894. TM Beer, CM Tangen, LB Bland, M Hussain, BH Goldman, TG DeLoughery, ED Crawford. <u>Cancer</u> 107(3):489-496, 2006.	GU	12/15/89	9/15/94
9024 (2218)	Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group study 9024. GP Swanson, J Faulkner, SR Smalley, MJ Noble, RL Stephens, TJ O'Rourke, GR Weiss, DP Quick, IM Thompson Jr, ED Crawford. <u>Journal of Urology</u> 176:548-553, 2006.	GU	8/1/91	3/15/95
9217 (2258)	Assessing prostate cancer risk: results from the prostate cancer prevention trial. IM Thompson, DP Ankerst, C Chi, PJ Goodman, CM Tangen, MS Lucia, Z Feng, HL Parnes, CA Coltman Jr. <u>Journal of the National Cancer Institute</u> 98(8):529-534, 2006	GU	10/13/93	12/6/96
9217 (2272)	Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. AR Kristal, C Chi, CM Tangen, PJ Goodman, R Etzioni, IM Thompson. <u>Cancer</u> 106(2): 320-328, 2006.	GU CC	10/13/93	12/6/96
9217 (2297)	Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the Prostate Cancer Prevention Trial. IM Thompson, C Chi, P Goodman, C Tangen, D Pauler Ankerst, MS Lucia, CA Coltman, Jr. Proc of the AUA, <u>Journal of Urology</u> 175(4) Suppl:152, (#470), 2006.	GU	10/13/93	12/6/96
9217 (2367)	Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. IM Thompson, C Chi, DP Ankerst, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr. <u>Journal of the National Cancer Institute</u> 98(16):1128-1133, 2006.	GU CC	10/13/93	12/6/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9217 (2374)	Modeling the effect of a preventive intervention on the natural history of cancer: application to the prostate cancer prevention trial. P Pinsky, R Etzioni, N Howlader, P Goodman, IM Thompson. <u>International Journal of Biostatistics</u> 2(1): article 12, 2006. Available at: http://www.bepress.com/ijb/vol2/iss1/12 .	GU CC	10/13/93	12/6/96
9217 (2337)	Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Z Gong, ML Neuhouser, PJ Goodman, D Albanes, C Chi, AW Hsing, SM Lippman, EA Platz, MN Pollak, IM Thompson, AR Kristal. <u>Cancer Epidemiol Biomarkers Prev</u> 15(10): 1977-1983.	GU CC	10/13/93	12/6/96
9217 (2193)	The prostate cancer prevention trial: design, biases, and interpretation of study results. PJ Goodman, IM Thompson Jr, CM Tangen, JJ Crowley, LG Ford, CA Coltman Jr. <u>Journal of Urology</u> 175:2234-2242, 2006.	GU CC	10/13/93	12/6/96
9346 (2275)	Absolute prostate specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162). M Hussain, CM Tangen, C Higano, PF Schellhammer, J Faulkner, ED Crawford, G Wilding, A Akdas, EJ Small, B Donnelly, G MacVicar, D Raghavan. <u>Journal of Clinical Oncology</u> 24(24):3984-3990, 2006.	GU	5/15/95	Open
9458 (2265)	Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group study. HB Grossman, CM Tangen, C Cordon-Cardo, R Cote, FM Waldman, RW De Vere White, AB Karnad, M Glode, ED Crawford. <u>Oncology Reports</u> 16:807-810, 2006.	GU	11/15/95	11/1/98
S9812 (2162)	Selenium accumulation in prostate tissue during a randomized controlled short-term trial of l-selenomethionine. A Southwest Oncology Group study. AL Sabichi, JJ Lee, RJ Taylor, IM Thompson, BJ Miles, CM Tangen, LM Minasian, LL Pisters, JR Caton, JW Basler, SP Lerner, DG Menter, JR Marshall, ED Crawford, SM Lippman. <u>Clinical Cancer Research</u> 12(7):2178-2184, 2006.	GU	6/15/99	6/1/01
S9916 (2189)	Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. D Petrylak, D Pauler Ankerst, CS Jiang, CM Tangen, MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, PA Burch, M Kohli, MC Benson, EJ Small, D Raghavan, ED Crawford. <u>Journal of the National Cancer Institute</u> 98(8):516-521, 2006.	GU	10/15/99	1/15/03
S9916 (2260)	Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. DL Berry, CM Moynour, CS Jiang, DP Ankerst, DP Petrylak, LV Vinson, PN Lara, S Jones, ME Taplin, PA Burch, MHA Hussain, ED Crawford. <u>Journal of Clinical Oncology</u> 24(18):2828-2835, 2006.	GU	10/15/99	1/15/03

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9917 (2310)	Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. JR Marshall, W Sakr, D Wood, D Berry, C Tangen, F Parker, I Thompson, SM Lippman, R Lieberman, D Alberts, D Jarrard, C Coltman, P Greenwald, L Minasian, ED Crawford. <u>Cancer Epidemiol Biomarkers Prev</u> 15(8):1479-1484, 2006.	CCRC GU	2/1/00	OPEN
S0000A (2378)	Studying the effects of vitamin E and selenium for alzheimer's disease prevention: the PREADVISE model. AM Caban-Holt, FA Schmitt, CR Runyons, RJ Kryscio, MS Mendiondo, MS Healey, WR Markesbery, CA Coltman, JJ Crowley, PJ Goodman, JL Hartline. In: <u>Research and Practice In Alzheimer's Disease Volume 11, 2006</u> , B Vellas, LJ Fitten, B Winblad, H Feldman, M Grundman, E Giacobini eds, Serdi Publishers 124-130, 2006.	CC GU	7/25/01	6/24/04
S0207 (2261)	Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. TM Beer, CM Tangen, CR Nichols, KA Margolin, R Dreicer, WT Stephenson, DI Quinn, D Raghavan, ED Crawford. <u>Cancer</u> 106(12):2624-2629, 2006.	GU	4/1/02	3/1/05
ABSTRACTS PUBLISHED/PRESENTED				
8794 (296)	Pre radiation PSA predicts for outcome of adjuvant radiation in SWOG 8794. GP Swanson, MA Hussey, IM Thompson, ED Crawford. Proc of the AUA, <u>Journal of Urology</u> 175(4) Suppl:216, (#668), 2006.	GU	8/15/88	1/1/97
8894 (2250)	Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894. TM Beer, BH Goldman, CM Tangen, LB Bland, M Hussain, TG DeLoughery, ED Crawford. Proc of the AUA, <u>Journal of Urology</u> 175(4) Suppl:385-386, (#1197), 2006.	GU	12/15/89	9/15/94
9217 (2249)	Association of erectile dysfunction and subsequent cardiovascular disease. IM Thompson Jr, J Probstfield, C Tangen, P Goodman, C Moinpour, CA Coltman Jr. Proc of the AUA, <u>Journal of Urology</u> 175(4) Suppl:429 (#1333), 2006.	GU	10/13/93	12/6/96
9346 (2248)	Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): data from Southwest Oncology Group trial 9346 (INT-0162). M Hussain, C Tangen, P Schellhammer, ED Crawford, C Higano, G Wilding, A Akdas, EJ Small, B Donnelly, D Raghavan. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#4517, 2006.	GU	5/15/95	Open

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0412 (2235)	Sorafenib plus interferon- α 2b (IFN) as first line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. CW Ryan, BH Goldman, PN Lara Jr, TM Beer, HA Drabkin, ED Crawford. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#4525, 2006.	GU	9/1/04	5/15/05

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9140 (1831)	A phase II clinical trial of oral bropiramine in combination with intravesical bacillus calmette-guerin for carcinoma in situ of the bladder; a Southwest Oncology Group study. MF Sarosdy, CM Tangen, GR Weiss, BR Nestok, MC Benson, PF Schellhammer, AI Sagalowsky, DP Wood Jr, ED Crawford. <u>Urologic Oncology</u> 23:386-389, 2005.	GU	12/1/92	12/1/97
9217 (2255)	Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. EA Klein, CM Tangen, PJ Goodman, SM Lippman, IM Thompson. <u>Journal of Clinical Oncology</u> 23(30): 7460-7466, 2005.	GU	10/13/93	12/6/96
9217 (2264)	Erectile dysfunction and subsequent cardiovascular disease. IM Thompson, CM Tangen, PJ Goodman, JL Probstfield, CM Moinpour, CA Coltman. <u>JAMA</u> 294(23):2996-3002, 2005.	GU	10/13/93	12/6/96
9217 (2069)	Estimated impact of the prostate cancer prevention trial on population mortality. JM Unger, IM Thompson Jr, M LeBlanc, JJ Crowley, PJ Goodman, LG Ford, CA Coltman Jr. <u>Cancer</u> 103(7):1375-1380, 2005.	GU	10/13/93	12/6/96
9217 (2298)	Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. RD Etzioni, N Howlader, PA Shaw, DP Ankerst, DF Penson, PJ Goodman, IM Thompson. <u>Journal of Urology</u> 174:877-881, 2005.	GU	10/13/93	12/6/96
9217 (2211)	Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. IM Thompson, DP Ankerst, C Chi, MS Lucia, PJ Goodman, JJ Crowley, HL Parnes, CA Coltman. <u>The Journal of the American Medical Association</u> 294(1):66-70, 2005.	GU	10/13/93	12/6/96
9217 (2365)	Phase III prostate cancer prevention trials: are the costs justified? IM Thompson, CM Tangen, EA Klein, SM Lippman. <u>Journal of Clinical Oncology</u> 23(32):8161-8164, 2005.	CC GU	10/13/93	12/6/96
9457 (2166)	Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. UN Vaishampayan, JR Faulkner, EJ Small, BG Redman, WL Keiser, DP Petrylak, ED Crawford. <u>Cancer</u> 104(8):1627-1632, 2005.	GU	7/15/96	4/15/00

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0000 (2093)	Centralized blood processing for the selenium and vitamin E Cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones and lymphocyte viability. AR Kristal, IB King, D Albanes, MN Pollak, FZ Stanzyk, RM Santella, A Hoque. <u>Cancer Epidemiology, Biomarkers & Prevention</u> 14(3):727-730, 2005.	GU	7/25/01	6/24/04
S0000 (2088)	Designing the selenium and vitamin E cancer prevention trial (SELECT). SM Lippman, PJ Goodman, EA Klein, HL Parnes, IM Thompson Jr, AR Kristal, RM Santella, JL Probstfield, CM Moinpour, D Albanes, PR Taylor, LM Minasian, A Hoque, SM Thomas, JJ Crowley, JM Gaziano, JL Stanford, ED Cook, NE Fleshner, MM Lieber, PJ Walther, FR Khuri, DD Karp, GG Schwartz, LG Ford, CA Coltman Jr. <u>Journal of the National Cancer Institute</u> 97(2):94-102, 2005.	GU	7/25/01	6/24/04
S0000 (2173)	Minority recruitment to the selenium and vitamin E cancer prevention trial (SELECT). ED Cook, SM Thomas, KB Anderson, R Campbell, SJ Hamilton, JM Harrington, SM Lippman, LM Minasian, ED Paskett, S Craine, KB Arnold, JL Probstfield. <u>Clinical Trials</u> 2:436-442, 2005.	GU	7/25/01	6/24/04
S0109 (2075)	A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group trial 0109. PJ Van Veldhuizen, JR Faulkner, PN Lara Jr, PH Gumerlock, JW Goodwin, SR Dakhil, HM Gross, RC Flanigan, ED Crawford. <u>Cancer Chemotherapy and Pharmacology</u> 56:39-45, 2005.	GU	5/1/01	2/1/02
S0111 (2252)	Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. M Hussain, CM Tangen, PN Lara Jr, UN Vaishampayan, DP Petrylak, AD Colevas, WA Sakr, ED Crawford. <u>Journal of Clinical Oncology</u> 23(34):8724-8729, 2005.	GU	6/15/01	11/15/03
ABSTRACTS PUBLISHED/PRESENTED				
*8710 (2206)	Optimal combined modality treatment improves outcome of locally advanced bladder cancer: analysis of SWOG 8710. ZA Dotan, DF Bajorin, BH Grossman, HW Herr. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16s):385s (#4531), 2005.	GU	8/1/87	7/1/98
*8794 (2145)	Adjuvant radiotherapy for pathologic T3 prostate cancer: results of a randomized, prospective clinical trial with metastasis-free survival endpoint. IM Thompson, C Tangen, G Miller, MS Lucia, D Troyer, J Paradelo, J Chin, E Messing, E Canby-Hagino, J Forman, ED Crawford. <u>Journal of Urology</u> 173(4):451 (#1665), 2005.	GU	8/15/88	1/1/97

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8794 (2267)	Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate Cancer (SOWG 8794). G Swanson, I Thompson, C Tangen, G Miller, MS Lucia, D Troyer, J Paradelo, J Chin, E Messing, E Canby-Hagino, J Forman, Ed Crawford. Proc ASTRO, <u>Int J Radiat Oncol Biol Phy</u> 63(Suppl1):S1 (#1), 2005.	GU	8/15/88	1/1/97
*8994 (2151)	Short-and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) trial. KA Hayden, CM Moinpour, J Faulkner, CM Tangen, ED Canby-Hagino, D Lemmon, S Breslin, IM Thompson, ED Crawford. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):391s (#4556), 2005.	GU	2/15/90	1/1/97
S9129 (2321)	Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL). J Gregory, H Kim, T Alonzo, R Gerbing, A Ogden, W Woods, H Weinstein, L Shepherd, C Schiffer, F Appelbaum, C Willman, P Wiernik, J Rowe, M Tallman, J Feusner. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #894, 2005.	Leuk	6/15/92	2/1/95
9217 (2291)	Individual prediction of prostate cancer based on prostate specific antigen. C Chi, D Pauler Ankerst, P Goodman. <u>Clinical Trials</u> 2 (Suppl 1):P40, 2005.	GU	10/13/93	12/6/96
*9217 (2146)	Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT). MS Lucia, A Darke, P Goodman, C Tangen, CA Coltman, IM Thompson. <u>Journal of Urology</u> 173(4):451 (#1664), 2005.	GU	10/13/93	12/6/96
*9217 (2147)	Prostate specific antigen (PSA) as a predictor of adverse pathological features at prostatectomy in the Prostate Cancer Prevention Trial (PCPT). MS Lucia, P Goodman, C Tangen, CA Coltman, IM Thompson. <u>Journal of Urology</u> 173(4):143 (#525), 2005.	GU	10/13/93	12/6/96
*9217 (2180)	The performance characteristics of prostate-specific antigen IM Thompson Jr, DP Ankerst, C Chi, P Goodman, C Tangen, CA Coltman Jr. <u>Journal of Urology</u> 173(4):143 (#526), 2005.	GU	10/13/93	12/6/96
S0000 (2196)	Minority participant accrual workshops-innovative strategy to increase African American accrual. RD Campbell. <u>Clinical Trials</u> 2(Suppl 1):S81 (#P80), 2005.	GU	7/25/01	6/24/04
S0000 (2197)	Minority recruitment to the selenium and vitamin e cancer prevention trial (SELECT). ED Cook, SM Thomas, KB Anderson, R Campbell, SJ Hamilton, JM Harrington, SM Lippman, LM Minasian, ED Paskett, S Craine, J Probstfield. <u>Clinical Trials</u> 2(Suppl 1):S82 (#P81), 2005.	GU	7/25/01	6/24/04
S0000 (2195)	Study-provided resources for quality pill counts. KB Gower. <u>Clinical Trials</u> 2(Suppl 1):S58 (#P29), 2005.	GU	7/25/01	6/24/04

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0000 (2194)	Supplemental financial support for minority recruitment: SELECT-selenium and vitamin E cancer prevention trial. KB Anderson, R Campbell, GB Gower, S Hamilton, W McCaskill-Stevens, L Minasian, SM Thomas, S Moon, F Stallings, J Probstfield. <u>Clinical Trials</u> 2(Suppl 1):S57 (#P25), 2005.	GU	7/25/01	6/24/04
S0000 (2198)	The black church: an invaluable ally for enhancing minority recruitment. JM Harrington, S Hamilton, R Campbell, S Moon, E Cook. <u>Clinical Trials</u> 2(Suppl 1):S24 (#05), 2005.	GU	7/25/01	6/24/04

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8710 (2081)	Pathologic evaluation of radical cystectomy specimens. A Cooperative Group report. HW Herr, JR Faulkner, HB Grossman, ED Crawford. <u>Cancer</u> 100(11):2470-2475, 2004.	GU	8/1/87	7/1/98
8710 (2080)	Surgical factors influence bladder cancer outcomes: a Cooperative Group report. HW Herr, JR Faulkner, HB Grossman, RB Natale, R de Vere White, MF Sarosdy, ED Crawford. <u>Journal Of Clinical Oncology</u> 22(14):2781-2789, 2004.	GU	8/1/87	7/1/98
8894 (2175)	Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894. TM Beer, CM Tangen, LB Bland, IM Thompson, ED Crawford. <u>Journal of Urology</u> 172(6, part 1 of 2):2213-2217, 2004.	GU	12/15/89	9/15/94
8949 (2112)	Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. RC Flanigan, G Mickisch, R Sylvester, C Tangen, H Van Poppel, ED Crawford. <u>Journal of Urology</u> 171:1071-1076, 2004.	GU	3/1/91	10/1/98
9217 (1494)	Implementation of the prostate cancer prevention trial (PCPT). PJ Goodman, CM Tangen, JJ Crowley, SM Carlin, A Ryan, CA Coltman Jr, LG Ford, IM Thompson. <u>Controlled Clinical Trials</u> 25:203-222, 2004.	GU	10/13/93	12/6/96
9217 (2074)	Prevalence of prostate cancer among men with a prostate-specific antigen level of <4.0 ng per milliliter. IM Thompson, DK Pauler, PJ Goodman, CM Tangen, MS Lucia, HL Parnes, LM Minasian, LG Ford, SM Lippman, ED Crawford, JJ Crowley, CA Coltman Jr. <u>New England Journal of Medicine</u> 350(22):2239-2246, 2004.	GU	10/13/93	12/6/96
9217 (2111)	The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. JM Unger, M LeBlanc, IM Thompson, CA Coltman, Jr. <u>Urologic Oncology: Seminars and Original Investigations</u> 22:362-368, 2004.	GU	10/13/93	12/6/96
9217/S0000 (2174)	Prostate cancer chemoprevention: an overview of United States trials. A Barqawi, IM Thompson, ED Crawford. <u>Journal of Urology</u> 171:S5-S9, 2004.	GU		
S9916 (2068)	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. DP Petrylak, CM Tangen, MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, PA Burch, D Berry, C Moinpour, M Kohli, MC Benson, EJ Small, D Raghavan, ED Crawford. <u>New England Journal of Medicine</u> 351(15):1513-1520, 2004.	GU	10/15/99	1/15/03

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9917 (2121)	Low rate of confirming prostate cancer on repeat biopsies following diagnosis of high grade prostatic intraepithelial neoplasia. Preliminary analysis of Southwest Oncology Group study S9917. WA Sakr, JR Faulkner, D Wood, I Thompson, D Crawford, S Lippman, C Coltman, J Marshall. <u>Proc of the American Association for Cancer Research</u> 45:305 (#1333), 2004.	GU	2/1/00	OPEN
None (2177)	First international conference on chemoprevention of prostate cancer. IM Thompson, D Albanes, JW Basler, ED Crawford, LJ Denis, B Djavan N Fleshner, TL Johnson-Pais, EA Klein, AR Kristal, MS Lucia, HL Parnes, GA Piazza, EA Platz, BH Pollock, DK Price, JK Reichardt, CM Tangen, AW Tolcher, MC McMann. <u>Journal of Urology</u> 171:S3-S4, 2004.	GU		
Statistical Paper (2082)	Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. CM Tangen, PJ Goodman, JJ Crowley, IM Thompson. <u>Journal of Urology</u> 171:S64-S67, 2004.	CC GU		

ABSTRACTS PUBLISHED/PRESENTED

8507 (2064)	Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 Bladder Cancer. a Southwest Oncology Group trial. SP Lerner, C Tangen, H Sucharew, DP Wood, ED Crawford. <u>Journal of Urology</u> 171(Suppl 4):72(#273), 2004.	GU	12/20/85	12/15/88
8894 (2179)	Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. LB Bland, CM Tangen, IM Thompson, ED Crawford, TM Beer. <u>Proc of the American Society of Clinical Oncology</u> 23:399 (#4574), 2004.	GU	12/15/89	9/15/94
9217 (2290)	The prostate cancer prevention trial: the association of study site and participant adherence interventions to the study site end-of-study biopsy rates. S Carlin, P Goodman, C Moinpour, C Tangen. <u>Clinical Trials</u> 1 (Suppl 1):P45, 2004.	GU	10/13/93	12/6/96
*S9916 (2050)	SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). DP Petrylak, C Tangen, M Hussain, PN Lara, J Jones, ME Taplin, P Burch, G Greene, E Small, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 23:2 (#3), 2004.	GU	10/15/99	1/15/03
*S9916 (2048)	Quality of life (QOL) and pain in advanced stage prostate cancer: Impact of missing data on evaluating palliation in SWOG 9916. DL Berry, CM Moinpour, C Jiang, LV Vinson, PN Lara, S Lanier, ME Taplin, PA Burch, DP Petrylak, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 23:400 (#4579), 2004.	GU	10/15/99	1/15/03

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S9916 (2049)	Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): data from Southwest Oncology Group study S9916. ED Crawford, DK Pauler, CM Tangen, MHA Hussain, EJ Small, ME Taplin, PA Burch, GF Greene, P Lara Jr, DP Petrylak. <u>Proc of the American Society of Clinical Oncology</u> 23:382 (#4505), 2004.	GU	10/15/99	1/15/03
*S0000 (2134)	Introducing HIPAA: triple the cost and triple the time for patient recruitment to the SELECT study. NS Gorby, MS Wolf, CL Bennett. <u>Proc of the American Society of Clinical Oncology</u> 23:519 (#6009), 2004.	GU	7/25/01	OPEN
S0000 (2094)	Participant's perception of recruitment and retention in the selenium and vitamin E cancer prevention trial. D Banerjee, JM Choe, D Ward, AM Hoque, K Basen-Engquist, J Song, D Ramsey, SM Lippman, ED Cook. <u>Proc of AACR Frontiers in Cancer Prevention Research</u> , Oct 16-20:131, 2004.	GU	7/25/01	6/24/04
*S0111 (2061)	Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology Group study (S0111). M Hussain, J Faulkner, U Vaishampayan, P Lara, D Petrylak, D Colevas, W Sakr, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 23:383 (#4510), 2004.	GU	6/15/01	11/15/03

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8710 (1844)	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. HB Grossman, RB Natale, CM Tangen, VO Speights, NJ Vogelzang, DL Trump, RW deVere White, MF Sarosdy, DP Wood Jr, D Raghavan, ED Crawford. <u>New England Journal of Medicine</u> 349(9):859-866, 2003.	GU	8/1/87	7/1/98
8792 (2422)	Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. EM Messing, J Manola, G Wilding, K Propert, J Fleischmann, ED Crawford, JE Pontes, R Hahn, D Trump. <u>Journal of Clinical Oncology</u> 21(7):1214-1222, 2003.	GU	6/15/87	4/8/92
8894 (1997)	Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. TR Glass, CM Tangen, ED Crawford, I Thompson. <u>Journal of Urology</u> 169:164-169, 2003.	GU	12/15/89	9/15/94
8894 (1984)	Ten-year survival in patients with metastatic prostate cancer. CM Tangen, JR Faulkner, ED Crawford, IM Thompson, D Hirano, M Eisenberger, M Hussain. <u>Clinical Prostate Cancer</u> 2(1):41-45, 2003.	GU	12/15/89	9/15/94
9217 (2020)	The influence of finasteride on the development of prostate cancer. IM Thompson, PJ Goodman, CM Tangen, MS Lucia, GJ Miller, LG Ford, MM Lieber, RD Cespedes, JN Atkins, SM Lippman, SM Carlin, A Ryan, CM Szczepanek, JJ Crowley, CA Coltman Jr. <u>New England Journal of Medicine</u> 349:215-224, 2003.	GU	10/13/93	12/6/96
9217 (1983)	The prostate cancer prevention trial: design, status, and promise. IM Thompson C Tangen, P Goodman. <u>World Journal of Urology</u> 21:28-30, 2003.	GU	10/13/93	12/6/96
9403 (1685)	A phase II study of 13-cis retinoic acid plus interferon a-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). RT Skeel, J Huang, J Manola, G Wilding, R Dreicer, P Walker, F Muggia, ED Crawford, JP Dutcher, PJ Loehrer. <u>Cancer Investigation</u> 21(1):41-46, 2003.	GU	3/1/96	6/17/98
S0000 (2485)	SELECT: the selenium and vitamin E cancer prevention trial. EA Klein, IM Thompson, SM Lippman, PJ Goodman, D Albanes, PR Taylor, C Coltman. <u>Urologic Oncology</u> 21(1):59-65, 2003. PMID: 12684129	CC GU	7/25/01	6/24/04
S0000 (2486)	The selenium and vitamin E cancer prevention trial. <u>World Journal of Urology</u> 21(1):21-27, 2003. PMID: 12756490	CC GU	7/25/01	6/24/04
Multiple Studies (2003)	Southwest Oncology Group studies in bladder cancer. ED Crawford, DP Wood, DP Petrylak, J Scott, CA Coltman Jr, D Raghavan. <u>Cancer Supplement</u> 97(8):2099-2108, 2003.	GU		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8710 (1879)	Surgical variables impact bladder cancer outcomes: a cooperative group report. H Herr, JR Faulkner, HB Grossman, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 22:383 (#1540), 2003.	GU	8/1/87	7/1/98
9217 (2289)	The prostate cancer prevention trial: Did the adherence interventions for the end of study biopsy really work? S Carlin, P Goodman, C Moinpour, S Hill. <u>Controlled Clinical Trials</u> 24(3S):P22, 2003.	GU	10/13/93	12/6/96
*9346 (1872)	Determinants of prostate specific antigen (PSA) normalization in prostate cancer (PCa) patients (pts) treated with androgen deprivation (AD) on Southwest Oncology Group (SWOG) study 9346 (INT-0162). CM Tangen, M Hussain, G Wilding, EJ Small, L Goldenberg, A Akdas, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 22:396 (#1591), 2003.	GU	5/15/95	Open
S0000 (2038)	Challenges of implementing ancillary studies within multi-site clinical trials. T Chay, P Goodman, J Hartline. <u>Controlled Clinical Trials</u> 24(3S) Suppl:182S (#P173), 2003.	GU	7/25/01	OPEN
S0000 (2040)	Drug distribution challenges in a multi-site clinical trial. A Darke, J Vertrees, P Goodman. <u>Controlled Clinical Trials</u> 24(3S) Suppl:203S (#P217), 2003.	GU	7/25/01	OPEN
S0000 (2031)	Effectiveness of a media based launch to recruit to a prostate cancer prevention trial. L Minasian, K Smigel-Crocker, A Ryan, A Voss, L Cave, E Klein, L Ford. <u>Controlled Clinical Trials</u> 24(3S) Suppl:50S (#14), 2003.	GU	7/25/01	OPEN
S0000 (2039)	Form and function: PDF+ versus HTML form design. KB Gower, B Kleinman. <u>Controlled Clinical Trials</u> 24(3S) Suppl:188S (#P186), 2003.	GU	7/25/01	OPEN
S0000 (2036)	Optimizing data collection in a large web-based trial. KB Gower, A Darke. <u>Controlled Clinical Trials</u> 24(3S) Suppl:47S (#10), 2003.	GU	7/25/01	OPEN
S0000 (2037)	Planning for successful recruitment for cancer trials. K Anderson, J Probstfield, SM Thomas. <u>Controlled Clinical Trials</u> 24(3S) Suppl:102S (#P18), 2003.	GU	7/25/01	OPEN
S0031 (1884)	Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group trial. D Petrylak, JR Faulkner, PJ Van Veldhuizen, M Mansukhani, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 22:403 (#1619), 2003.	GU	2/15/01	10/15/02
*S0109 (1875)	A phase II study of flavopiridol (Flavo) in patients (pts) with advanced renal cell cancer: results of Southwest Oncology Group trial S0109. PJ Van Veldhuizen, JR Faulkner, PN Lara, RC Flanigan, PH Gumerlock, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 22:387 (#1553), 2003.	GU	5/1/01	2/1/02

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8894 (1838)	Impact of previous local treatment for prostate cancer on subsequent metastatic disease. IM Thompson, C Tangen, J Basler, and ED Crawford. <u>Journal of Urology</u> 168:1008-1012, 2002.	GU	12/15/89	9/15/94
8949 (1847)	The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. RA Gatenby, ET Gawlinski, CM Tangen, RC Flanigan, ED Crawford. <u>Cancer Research</u> 62:5218-5222, 2002.	GU	3/1/91	10/1/98
9109 (1818)	Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5 year follow-up, phase II Southwest Oncology Group study 9109. IJ Powell, CM Tangen, GJ Miller, BA Lowe, G Haas, PR Carroll, MB Osswald, R deVere-White, IM Thompson Jr, ED Crawford. <u>Journal of Urology</u> 168:2016-2019, 2002.	GU	12/1/93	10/15/96
9217 (1857)	Biomarker-based methods for determining noncompliance in a prevention trial. DK Pauler, KB Gower, PJ Goodman, JJ Crowley, IM Thompson. <u>Controlled Clinical Trials</u> 23: 675-685, 2002.	GU	10/13/93	12/6/96
9217 (1765)	Energy from fat is associated with obesity in US men: results from the Prostate Cancer Prevention Trial. J Satia-Abouta, RE Patterson, RN Schiller, AR Kristal. <u>Preventive Medicine</u> 34:493-501, 2002.	GU	10/13/93	12/6/96
9230 (1782)	Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. RP Whitehead, D Lew, RC Flanigan, GR Weiss, V Roy, ML Glode, SR Dakhil, ED Crawford. <u>Journal of Immunotherapy</u> 25(4):352-358, 2000.	GU	6/1/93	5/1/95
9452 (1982)	Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. EJ Small, S Halabi, MJ Ratain, G Rosner, W Stadler, D Palchak, E Marshall, R Rago, V Hars, G Wilding, D Petrylak, NJ Vogelzang. <u>Journal of Clinical Oncology</u> 20(16): 3369-3375, 2002.	GU	10/1/96	7/15/98
9510 (1770)	SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. CE Klein, CM Tangen, TJ Braun, MHA Hussain, DM Peereboom, CR Nichols, SE Rivkin, SR Dakhil, ED Crawford.	GU	11/1/96	8/15/99

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	<u>The Prostate</u> 52:264-268, 2002.			
S0000 (1993)	The Das/Kaplan article reviewed: The role of PC-SPES, selenium, and vitamin E in prostate cancer. EA Klein. <u>Oncology</u> 16(3):296-300, 2002.	GU	7/25/01	Open
S0000 (1992)	The Das/Kaplan article reviewed: The role of PC-SPES, selenium, and vitamin E in prostate cancer. EJ Small. <u>Oncology</u> 16(3):291-296, 2002.	GU	7/25/01	Open
ABSTRACTS PUBLISHED/PRESENTED				
8894 (1801)	Ten-year survival in patients with metastatic (M+) prostate cancer (CAP): analysis of Southwest Oncology Group (SWOG) 8894. D Crawford, J Faulkner, IM Thompson, MA Eisenberger, CM Tangen, MH Hussain. <u>Journal of Urology</u> 167(4) Suppl:304 (#1202), 2002.	GU	12/15/89	9/15/94
8894 (1870)	Ten-year survival in patients with metastatic (M+) prostate cancer (CaP): analysis of Southwest Oncology Group (SWOG) 8894. C Tangen, ED Crawford, J Faulkner, I Thompson, M Eisenberger, M Hussain. <u>Proc of the American Society of Clinical Oncology</u> 21:188a (#749), 2002.	GU	12/15/89	9/15/94
8894 (1901)	The relationship of gleason sum and survival in patients with metastatic (M+) prostate cancer (CaP): analysis of SWOG 8894. ED Crawford, G Miller, J Faulkner, C Tangen, IM Thompson, E Eisenberger, M Hussain. <u>South Central Section of the AUA</u> , 81 st Annual Meeting:170 (#31), 2002.	GU	12/15/89	9/15/94
9023 (1784)	Cytogenetic and flow cytometric results in advanced renal cell carcinoma: a Southwest Oncology Group study. RP Whitehead, C Tangen, SR Wolman, RC Flanigan, TV Shankey, ML Slovak, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 21:147b (#2400), 2002.	GU	7/1/93	11/1/98
9217 (1855)	Biomarker-based methods for determining non-compliance in a prevention trial. KB Gower, DK Pauler, PJ Goodman. <u>Controlled Clinical Trials</u> 23(2S):49S-50S (#26), 2002.	GU	10/13/93	12/6/96
9426 (1791)	Anti-Androgen withdrawal in prostate cancer: results from SWOG 9426. AO Sartor, C Tangen, M Hussain, M Eisenberger, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 21:197a (#785), 2002.	GU	3/15/95	6/1/01
9458 (1832)	SWOG 9458: evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 8710. HB Grossman, C Cordon-Cardo, R Cote, FM Waldman, C Tangen, ED Crawford. <u>International Journal of Cancer</u> Suppl 13:114 (#O 140), 2002.	GU	11/15/95	11/1/98
9812	Selenium accumulates in prostate tissue of prostate cancer	GU	6/15/99	6/1/01

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1828)	patients after short-term administration of I –selenomethionine. AL Sabichi, JJ lee, RJ Taylor, IM Thompson Jr, BJ Miles, JW Basler, LL Platera, M Wargo, D Menter, CM Tangen, ED Crawford, SM Lippman. <u>Proc of the American Association for Cancer Research</u> 43:1007 (#4993), 2002.			
S0000 (1856)	The challenges and benefits of a web-based trial. B Kleinman, A Darke, JA Hartline. <u>Controlled Clinical Trials</u> 23(2S):91S-92S (#P 62), 2002.	GU/CCR	7/25/01	OPEN

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8894 (1630)	Association of African-American ethnic background with survival in men with metastatic prostate cancer. IM Thompson, CM Tangen, A Tolcher, ED Crawford, M Eisenberger, CM Moinpour. <u>Journal of the National Cancer Institute</u> 93(3):219-225, 2001.	GU	12/15/89	9/15/94
8894 (1915)	Response to Letter to the Editor: RE: Association of African-American ethnic background with survival in men with metastatic prostate cancer. A Tolcher, ED Crawford, M Eisenberger, CM Moinpour. <u>Journal of the National Cancer Institute</u> 93(15):1175, 2001.	GU	12/15/89	9/15/94
8949 (1740)	Nephrectomy followed by interferon Alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. RC Flanigan, SE Salmon, BA Blumenstein, SI Bearman, V Roy, PC McGrath, JR Caton, Jr, N Munshi, ED Crawford. <u>New England Journal of Medicine</u> 345(23):1655-1659, 2001.	GU	3/1/91	10/1/98
9217 (1809)	Dietary supplement use in the prostate cancer prevention trial: implications for prevention trials. ML Neuhausser, AR Kristal, RE Patterson, PJ Goodman, IM Thompson. <u>Nutrition and Cancer</u> 39(1):12-18, 2001.	GU	10/13/93	12/6/96
9217 (1745)	The prostate cancer prevention trial: current status and lessons learned. IM Thompson Jr, J Kouril, EA Klein, CA Coltman, A Ryan, P Goodman. <u>Urology</u> 57(Suppl 4A):230-234, 2001.	GU	10/13/93	12/6/96
9235 (1559)	Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). O Kucuk, E Fisher, CM Moinpour, D Coleman, MHA Hussain, AO Sartor, GS Chatta, BA Lowe, MA Eisenberger, ED Crawford. <u>Urology</u> 58(1):53-58, 2001.	GU	12/15/93	6/1/94
9312 (1635)	Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group study. MHA Hussain, TR Glass, J Forman, W Sakr, DC Smith, M Al-Sarraf, J Jones, SP Balcerzak, ED Crawford, HB Grossman. <u>Journal of Urology</u> 165:56-61, 2001.	GU	10/1/93	4/1/98
9407 (1595)	A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group trial (SWOG-9407). KJ Pienta, EI Fisher, MA Eisenberger, GM Mills, JW Goodwin, JA Jones, SR Dakhil, ED Crawford,	GU	3/1/96	7/1/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	MHA Hussain. <u>The Prostate</u> 46:257-261, 2001.			
9461 (1675)	Phase II evaluation of suramin in advanced renal cell carcinoma: a Southwest Oncology Group study. LE Schroder, D Lew, RC Flanigan, MA Eisenberger, TE Seay, N Hammond, BM Needles, ED Crawford. <u>Urologic Oncology</u> 6:145-148, 2001.	GU	2/1/97	6/15/99
S0000 (1741)	Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT). A Hoque, D Albanes, SM Lippman, MR Spitz, PR Taylor, EA Klein, IM Thompson, P Goodman, JL Stanford, JJ Crowley, CA Coltman, RM Santella. <u>Cancer Causes and Control</u> 12:627-633, 2001.	GU/CCR		
S0000 (1764)	SELECT: The next prostate cancer prevention trial. EA Klein, IM Thompson, SM Lippman, PJ Goodman, D Albanes, PR Taylor, C Coltman. <u>Journal of Urology</u> 166:1311-1315, 2001.	GU		
ABSTRACTS PUBLISHED/PRESENTED				
*8710 (1730)	SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. D Crawford, B Grossman, B Blumenstein, N Vogelzang, D Trump, VO Speights, RW DeVere White, R Natale. <u>Journal of Urology</u> 165(5) Suppl:260 (#1069), 2001.	GU	8/1/87	7/1/98
*8710 (1737)	SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. RB Natale, HB Grossman, B Blumenstein, N Vogelzang, DL Trump, VO Speights, R de Vere White, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 20:2a (#3), 2001.	GU	8/1/87	7/1/98
*8894 (1739)	Does a prior radical prostatectomy (RP) alter outcome of hormonal therapy for metastatic (M+) prostate cancer (CAP). IM Thompson, J Basler, C Tangen, ED Crawford. <u>Journal of Urology</u> 165(5) Suppl:168 (#689), 2001.	GU	12/15/89	9/15/94
9109 (1715)	Neoadjuvant zoladex and flutamide in bulky and non-bulky clinical stage C carcinoma of the prostate. IJ Powell, CM Tangen, GP Haas, D Crawford, GJ Miller, BA Lowe, IM Thompson. <u>Journal of Urology</u> 165(5) Suppl:330 (#1355), 2001.	GU	12/1/93	10/15/96
9217 (1767)	Promoting adherence to the prostate cancer prevention trial end of study biopsy requirement. AM Ryan, P Goodman, S Hill, C Moinpour. <u>Controlled Clinical Trials</u> 22(2S):88S (#P71), 2001.	GU	10/13/93	12/6/96
9427	Phase II evaluation of suramin in advanced adrenal carcinoma	GU	3/1/97	6/1/00

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1725)	Southwest Oncology Group (SWOG) trial 9427. LE Schroder, T Glass, M Eisenberger, D Culkin, R Bukowski, E Crawford. <u>Proc of the American Society of Clinical Oncology</u> 20:153b (#2361), 2001.			
S0000 (1766)	The web-based management of the selenium and vitamin E cancer prevention trial. PA Shaw, PJ Goodman, J Brace. <u>Controlled Clinical Trials</u> 22(2S):57S (#P06), 2001.	GU		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8507 (1544)	Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. DL Lamm, BA Blumenstein, JD Crissman, JE Montie JE Gottesman, BA Lowe, MF Sarosdy, RD Bohl, HB Grossman, TM Beck, JT Leimert, ED Crawford. <u>Journal of Urology</u> 163:1124-1129, 2000.	GU	12/20/85	12/15/88
8795 (1477)	The prognostic significance of s-phase analysis in stage Ta/T1 bladder cancer: A Southwest Oncology Group study. RW deVere White, AD Deitch, S Daneshmand, B Blumenstein, BA Lowe, AI Sagalowsky, JA Smith, Jr, PF Schellhammer, TH Stanistic, HB Grossman, E Messing, JD Crissman, ED Crawford. <u>European Urology</u> 37:595-600, 2000.	GU	12/1/88	5/15/92
8925 (1547)	Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study. SK Williamson, D Lew, GJ Miller, SP Balcerzak, LH Baker, ED Crawford. <u>Cancer</u> 88(5):1159-1165, 2000.	GU	6/15/89	12/1/95
9217 (1667)	Letters to the editor: RE: RE: Chemoprevention of Urological Cancer. IM Thompson, CA Coltman. <u>Journal of Urology</u> 164(4):1321-1322, 2000.	GU	10/13/93	12/6/96
9217 (1669)	Minority recruitment in the prostate cancer prevention trial. CM Moinpour, JO Atkinson, SM Thomas, S Millon Underwood, C Harvey, J Parzuchowski, LC Lovato, AM Ryan, MS Hill, E DeAntoni, ER Gritz, IM Thompson Jr, CA Coltman Jr. <u>Annals of Epidemiology</u> 10(S8):S85-S91, 2000.	GU	10/13/93	12/6/96
9217 (1517)	Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. CM Moinpour, LC Lovato, IM Thompson Jr, JE Ware Jr, PA Ganz, DL Patrick, SA Shumaker, GW Donaldson, A Ryan, CA Coltman Jr. <u>Journal of Clinical Oncology</u> 18(9):1942-1953, 2000.	GU	10/13/93	12/6/96
9217 (1398)	Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. TDK Chung, II Park, L Ignacio, R Catchatourian, M Kopnick, E Davison, G Conrad, AM Awan, D Crawford, S. Vijayakumar. <u>International Journal of Cancer</u> 90:302-304,	GU	10/13/93	12/6/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	2000.			
9338 (1520)	Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-a for the treatment of patients with advanced renal cell carcinoma: A Southwest Oncology Group phase II study. L Elias, D Lew, RA Figlin, RC Flanigan, ME Thompson, PL Triozzi, RJ Belt, DP Wood Jr, SE Rivkin, ED Crawford. <u>Cancer</u> 89(3):597-603, 2000.	GU	12/15/94	9/1/97
9343 (1543)	Androgen deprivation and four-courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group study. M Hussain, EI Fisher, DP Petrylak, J O'Connor, DP Wood, EJ Small, MA Eisenberger, ED Crawford. <u>Journal of Clinical Oncology</u> 18(5):1043-1049, 2000.	GU	8/15/94	1/15/97
9457 (1557)	Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. EJ Small D Lew, BG Redman, DP Petrylak, N Hammond, HM Gross, JA Eastham, ED Crawford. <u>Journal of Clinical Oncology</u> 18(13):2537-2544, 2000.	GU	7/15/96	9/15/98
S0000 (1656)	SELECT: the selenium and vitamin E cancer prevention trial rationale and design. EA Klein, IM Thompson, SM Lippman, PJ Goodman, D Albanes, PR Taylor, C Coltman. <u>Prostate Cancer and Prostatic Diseases</u> 3:145-151, 2000.	GU		
NONE (1742)	Selenium effects on prostate cell growth. DG Menter, AL Sabichi, SM Lippman. <u>Cancer Epidemiology & Prevention</u> 9:1171-1182, 2000.	GU/CCR		

ABSTRACTS PUBLISHED/PRESENTED

8894 (1612)	African American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer. I Thompson, A Tolcher, ED Crawford, M Eisenberger, C Tangen, E Fisher. <u>Journal of Urology</u> 163(4):56 Suppl (#242), 2000.	GU	12/15/89	9/15/94
8894 (1623)	Prognostic value of serum PSA in patients with newly diagnosed metastatic prostate cancer. D Crawford, I Thompson, A Tolcher. <u>Journal of Urology</u> 163(4):259 Suppl (#1149), 2000.	GU	12/15/89	6/15/94
*8949 (1678)	Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949. RC Flanigan, BA Blumenstein, S Salmon, E Crawford. <u>Proc of the American Society of Clinical Oncology</u> 19:2a (#3), 2000.	GU	3/1/91	10/1/98
8949 (1613)	Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949. RC	GU	3/1/91	10/1/98

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	Flanigan, BA Blumenstein, S Salmon, SI Bearman, V Roy, SP Balcerzak, PC McGrath, JR Caton, B Barlogie, ED Crawford. <u>Journal of Urology</u> 163(4) Suppl:154, (#685), 2000.			
*9217 (1644)	Dietary supplement use in the prostate cancer prevention trial: implications for study findings. ML Neuhouster, AR Kristal, RE Patterson, IM Thompson. <u>American Society of Prevention Oncology</u> #76, 2000.	GU	10/13/93	12/6/96
*9452 (1615)	Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC). S Halabi, EJ Small, RH Ansari, G Wilding, DP Petrylak, DI Palchak, E Marshall, RP Rago, V Hars, NJ Vogelzang. <u>Proc of the American Society of Clinical Oncology</u> 19:328a (#1291), 2000.	GU	10/1/96	7/15/98
0000 (1617)	Design of the selenium and vitamin E chemoprevention trial (SELECT). PJ Goodman, S Lippman, E Klein, A Ryan, J Crowley, M LeBlanc, CA Coltman Jr. <u>Proc of the Society for Clinical Trials</u> #11, 2000.	GU		

*Presented

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

8507 (1497)	Maintenance BCG Immunotherapy: Evidence of additional protection against cancer: A Southwest Oncology Group study. DL Lamm, JD Crissman, JE Montie, JB Gottesman, BA Lowe, MF Sarosdy, RD Bohl, HB Grossman, TM Beck, JT Leimert, ED Crawford, U Kosecka, RC Wittes. <u>Proc of the American Urological Association</u> #1464, 1999.	GU	12/20/85	12/15/88
8793 (1523)	Immediate hormonal therapy vs observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized phase III Eastern Cooperative Oncology Group/Intergroup trial. E Messing, G Wilding, M Sarosdy, D Crawford, J Manola. <u>Proc of the American Urological Association</u> #45, 1999.	GU	3/15/88	4/15/93
*9312 (1498)	Phase II evaluation of cisplatin + 5-fluorouracil + radiation therapy in patients with locally advanced/inoperable bladder cancer. A Southwest Oncology Group study 9312. M Hussain, E Fisher, J Forman, W Sakr, A Drelichman, S Akhter, HB Grossman, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:333a (#1281), 1999.	GU	10/1/93	4/1/98
*9338 (1503)	Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon- α for advanced renal cell carcinoma. A Southwest Oncology Group study. L Elias, D Lew, RA Figlin, RC Flanigan, ME Thompson, PL Triozzi, RJ Belt, DP Wood, SE Rivkin, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:331a (#1275), 1999.	GU	12/15/94	9/1/97
*9457 (1502)	Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium. EJ Small, D Lew, DP Petrylak, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:333a (#1280), 1999.	GU	7/15/96	OPEN

*Presented

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

8507 (1497)	Maintenance BCG Immunotherapy: Evidence of additional protection against cancer: A Southwest Oncology Group study. DL Lamm, JD Crissman, JE Montie, JB Gottesman, BA Lowe, MF Sarosdy, RD Bohl, HB Grossman, TM Beck, JT Leimert, ED Crawford, U Kosecka, RC Wittes. <u>Proc of the American Urological Association</u> #1464, 1999.	GU	12/20/85	12/15/88
8793 (1523)	Immediate hormonal therapy vs observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized phase III Eastern Cooperative Oncology Group/Intergroup trial. E Messing, G Wilding, M Sarosdy, D Crawford, J Manola. <u>Proc of the American Urological Association</u> #45, 1999.	GU	3/15/88	4/15/93
*9312 (1498)	Phase II evaluation of cisplatin + 5-fluorouracil + radiation therapy in patients with locally advanced/inoperable bladder cancer. A Southwest Oncology Group study 9312. M Hussain, E Fisher, J Forman, W Sakr, A Drelichman, S Akhter, HB Grossman, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:333a (#1281), 1999.	GU	10/1/93	4/1/98
*9338 (1503)	Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon- α for advanced renal cell carcinoma. A Southwest Oncology Group study. L Elias, D Lew, RA Figlin, RC Flanigan, ME Thompson, PL Triozzi, RJ Belt, DP Wood, SE Rivkin, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:331a (#1275), 1999.	GU	12/15/94	9/1/97
*9457 (1502)	Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium. EJ Small, D Lew, DP Petrylak, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 18:333a (#1280), 1999.	GU	7/15/96	OPEN

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8894 (1383)	Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. MA Eisenberger, BA Blumenstein, ED Crawford, G Miller, DG McLeod, PJ Loehrer, G Wilding, K Sears, DJ Culkin, IM Thompson Jr, AJ Bueschen, BA Lowe. <u>New England Journal of Medicine</u> 339:1036-1042, 1998.	GU	12/15/89	9/15/94
8997 (1413)	Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. CR Nichols, PJ Catalano, ED Crawford, NJ Vogelzang, LH Einhorn, PJ Loehrer. <u>Journal of Clinical Oncology</u> 16(4):1287-1293, 1998.	GU	10/1/89	4/9/92
9039 (1388)	Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. CM Moynour, MJ Savage, A Troxel, LC Lovato, M Eisenberger, RW Veith, B Higgins, R Skeel, M Yee, BA Blumenstein, ED Crawford, FL Meyskens Jr. <u>Journal of the National Cancer Institute</u> 90(20):1537-1544, 1998.	CCR GU	10/1/90	9/15/94
9217 (1356)	Army and Air Force leadership in the prostate cancer prevention trial. J Allerton, T Seay, S Optenberg, CA Coltman Jr, B Higgins, I Thompson, L Lovato. <u>Urology</u> 51 (Suppl 4A):64-66, 1998.	GU	10/13/93	12/6/96
None (1367)	Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas. DF Brown, MA Dababo, CL Hladik, KP Eagan, CL White, EJ Rushing. <u>Modern Pathology</u> 11(1):55-59, 1998.	GU		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

*8795 (1481)	Predictors of outcome in bladder transitional cell carcinoma (TCC) treated by intravesical chemotherapy. R deVere White, AD Deitch, S Daneshmand, BA Blumenstein. <u>The Journal of Urology</u> 159(5) Suppl:145 (#552), 1998.	GU	12/1/88	5/15/92
9343 (1378)	Analysis of suramin (S) levels obtained from D ₂ hormone naive prostate cancer (HNPCC) patients (pts) treated with fixed bolus suramin: A Southwest Oncology Group study. DP Petrylak, JO Connor, E Fisher, M Eisenberger, ED Crawford, M Hussain. <u>Proc of the American Society of Clinical Oncology</u> 17:340a (#1310), 1998.	GU	8/15/94	1/15/97
*9343 (1377)	Androgen deprivation (AD) + 4-courses of fixed-schedule suramin in D2 prostate cancer (PCA) patients (pts): A Southwest Oncology Group phase II study. M Hussain, E Fisher, D Wood, E Small, M Eisenberger, ED Crawford. <u>Proc of the American Society of Clinical Oncology</u> 17:314a (#1211), 1998.	GU	8/15/94	1/15/97

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8221 (1138)	Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone. A Phase III intergroup study. JA Smith Jr, ED Crawford, JC Paradelo, B Blumenstein, BR Herschman, HB Grossman, DW Christie. <u>Journal of Urology</u> 157:805-808, 1997.	GU	10/29/82	11/15/89
8594 (1353)	Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. SB Saxman, KJ Propert, LH Einhorn, ED Crawford, I Tannock, D Raghavan, PJ Loehrer, D Trump. <u>Journal of Clinical Oncology</u> 15(7):2564-2569, 1997.	GU	10/1/84	5/15/89
8711 (1189)	A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). W Gordon Jr, K Siegmund, TH Stanisic, B McKnight, IT Harris, PR Carroll, JC Paradelo, FJ Meyers, RA Chapman, FL Meyskens Jr. <u>International Journal of Radiation Oncology Biology Physics</u> 38(1):83-94, 1997.	CCR GU	4/1/88	6/1/94
8956 (1114)	Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial. JA Kish, MK Wolf, PF Schellhammer, MHA Hussain, AB Einstein, ED Crawford. <u>American Journal of Clinical Oncology (CCT)</u> 20(4):327-330, 1997.	GU	10/1/90	6/15/93
9104 (1191)	Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of p-glycoprotein in patients with advanced renal carcinoma. LE Schroder, BA Blumenstein, RC Flanigan, JR Borst, ED Crawford. <u>Urologic Oncology</u> 3:94--98, 1997.	GU	9/1/92	9/1/94
9217 (1334)	Chemoprevention of prostate cancer: The prostate cancer prevention trial. IM Thompson, CA Coltman Jr, J Crowley. <u>The Prostate</u> 33:217-221, 1997.	GU	10/13/93	12/6/96
9450 (1359)	The prostate cancer intervention versus observation trial TJ Wilt, MK Brawer. <u>Oncology</u> 11(8):1133-1139, 1997.	GU	5/12/95	
Multiple Studies (1309)	Prostate cancer clinical trials of the Southwest Oncology Group. ED Crawford, EP DeAntoni, M Hussain, IM Thompson, CA Coltman Jr. <u>Oncology</u> 11(8):1154-1170, 1997.	GU		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
Multiple Studies (1322)	Towards the validation of aneusomy detection by fluorescence in situ hybridization (FISH) in bladder cancer: Comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations. FF Zhang, DA Arber, TG Wilson, MH Kawachi, ML Slovak. <u>Clinical Cancer Research</u> 3:2317-2328, 1997.	GU Cytogenetics		
ABSTRACTS PUBLISHED/PRESENTED				
8507 (1229)	Significant long-term patient benefit with BCG maintenance therapy: A Southwest Oncology Group study. DL Lamm, B Blumenstein, M Sarosdy, HB Grossman, ED Crawford. <u>Urology</u> 157(4)(Suppl)(#831):213, 1997.	GU	12/20/85	12/15/88
*8894 (1268)	A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG). M Eisenberger, ED Crawford, D McLeod, P Loehrer, G Wilding, B Blumenstein. <u>American Society of Clinical Oncology</u> 16:2a (#3), 1997.	GU	12/15/89	9/15/94
8894 (1230)	Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (pts) with stage D ₂ adenocarcinoma of the prostate (CaP): Results of NCI Intergroup study 0105 (SWOG and ECOG). ED Crawford, MA Eisenberger, DG McLeod, G Wilding, BA Blumenstein. <u>Urology</u> 157(4)(Suppl) (#1311):336, 1997.	GU	12/15/89	9/15/94
*8894 (1341)	Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (pts) with stage D ₂ adenocarcinoma of the prostate (CaP): Results of the NCI intergroup study 0105 (SWOG and ECOG). ED Crawford, M Eisenberger, DG McLeod, G Wilding, BA Blumenstein. <u>British Journal of Urology</u> 80(Suppl 2): 278 (#1092), 1997.	GU	12/15/89	9/15/94
8956 (1298)	High dose cisplatin (C) and continuous infusion 5 fluorouracil (5FU CI) for the treatment of advanced/ recurrent transitional cell cancer of the bladder (ARTCCB). Final report of a Southwest Oncology Group (SWOG) trial. J Kish, M Wolf, P Schellhammer, M Hussain, A Einstein, E Crawford. <u>Proc Seventh International Congress on Anti-Cancer Treatment</u> #254, 1997.	GU	10/1/90	6/15/93
9024 (1419)	Protracted venous infusion (PVI) 5-FU and radiation as definitive therapy for stage C prostate cancer – a Southwest Oncology Group phase II study. S Smalley, D Lew, I Thompson, M Sarosdy, R Stephens, M Noble, B Kimler. <u>Proc of the American Society of Clinical Oncology</u> 16:343a (#1228), 1997.	GU	8/1/91	3/15/95

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9023 (1250)	Comparison of cytogenetic and flow cytometric results of renal cell carcinoma (RCC) performed in the Southwest Oncology Group (SWOG). SM Dobin, TS McConnell, ML Slovak, R Whitehead, V Shankey, R Flanigan. <u>Proc Seventh International Workshop on Chromosomes in Solid Tumors #21, 1997.</u>	Cytogenetics GU	7/1/93	Open
*9039 (1265)	Quality of life (QOL) endpoints in advanced stage prostate cancer: a randomized, double blind study comparing flutamide to placebo in orchiectomized stage D ₂ prostate patients (pts). CM Moinpour, M Savage, L Lovato, A Troxel, R Skeel, MA Eisenberger, ED Crawford, FL Meyskens Jr. <u>American Society of Clinical Oncology 16:53a (#183), 1997.</u>	GU	10/1/90	9/15/94
*9217 (1335)	Utility of the enrollment period in the Prostate Cancer Prevention Trial (PCPT). PJ Goodman, L Lovato, A Ryan, J Crowley, C Moinpour, I Thompson. <u>Controlled Clinical Trials 18(3S)(#19):52S, June 1997.</u>	GU	10/13/93	12/6/96
*9217 (1336)	Data operations management with clinical datafax: The prostate cancer prevention trial (PCPT) experience. AM Ryan, L Emel, P Goodman. <u>Controlled Clinical Trials 18(3S):156S (#P74), June 1997.</u>	GU	10/13/93	12/6/96
None (1290)	Aneusomy detection by fluorescence in situ hybridization (FISH) using bladder washings: Correlation with cytology, cytogenetics and clinical features predicts recurrence and defines test limitations. ML Slovak, F Zhang, T Wilson, MH Kawachi, DA Arber, TS McConnell, SM Dobin. <u>Proc Seventh International Workshop on Chromosomes in Solid Tumors #20, 1997.</u>	GU		
None (1269)	Comparison of fluorescence in-situ hybridization (FISH) and bladder tumor antigen test (BTA®) in bladder cancer: A pilot study. TS McConnell, AY Smith, LA Haines Jr, T Cushing, ED Crawford, M Slovak. <u>Proc Seventh International Workshop on Chromosomes in Solid Tumors #A22, 1997.</u>	GU		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8216 (1135)	Local toxicity patterns associated with intravesical bacillus calmette-guérin: A Southwest Oncology Group study. DL Berry, BA Blumenstein, DL Magyary, DL Lamm, ED Crawford. <u>International Journal of Urology</u> 3:98-100, 1996.	GU	12/1/82	2/15/90
8704 (631)	Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: A phase I/II Southwestern Oncology Group study. AB Einstein Jr, M Wolf, KR Halliday, GJ Miller, M Hafermann, BA Lowe, FJ Meyers, JT Leimert, ED Crawford. <u>Urology</u> 47(5):652-657, 1996.	GU	9/1/87	8/15/91
8719 (1094)	Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. SK Williamson, MK Wolf, MA Eisenberger, MA O'Rourke, W Brannan, ED Crawford. <u>American Journal of Clinical Oncology (CCT)</u> 19(4):368-370, 1996.	GU	11/1/88	5/15/93
8795 (1139)	Prognostic significance of DNA ploidy in Ta/T1 bladder cancer: A Southwest Oncology Group study. RW deVere White, AD Deitch, H Tesluk, B Blumenstein, BA Lowe, AI Sagalowsky, JA Smith Jr, PF Schellhammer, TH Stanisic, HB Grossman, E Messing, JD Crissman, ED Crawford. <u>Urologic Oncology</u> 2:27-34, 1996.	GU	12/1/88	5/15/92
8955 (1158)	Treatment of stage D ₂ hormone refractory carcinoma of the prostate with 5-fluorouracil and roferon-A [®] : A Southwest Oncology Group study. ME Marshall, M Wolf, M O'Rourke, TC Barnett, ED Crawford. <u>Cancer Biotherapy & Radiopharmaceuticals</u> 11(2):119-123, 1996.	GU	6/15/92	11/1/93
9122 (1184)	A phase II trial of interferon-a and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. L Elias, BA Blumenstein, J Kish, RC Flanigan, JL Wade, BA Lowe, JW Goodwin, ED Crawford. <u>Cancer</u> 78:1085-1088, 1996.	GU	6/1/92	10/15/93
9217 (1174)	Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C Coltman. <u>Principles & Practice of Oncology</u> 10(3):1-18, 1996.	GU	10/13/93	Open
9217 (1173)	Screening for prostate cancer: Opportunities for prevention. IM Thompson, CA Coltman. <u>Seminars in Urologic Oncology</u> 14(2) (Suppl 2):4-11, 1996.	GU	10/13/93	Open
None (1201)	Southwest Oncology Group studies in hormone-refractory prostate cancer. MHA Hussain, B Blumenstein, M Eisenberger, ED Crawford. <u>Seminars in Oncology</u> 23(6) (Suppl 14):24-27, 1996.	GU		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*9217 (1172)	Prostate cancer prevention trial. BH Zoltick. Presented at the <u>AUAA</u> Annual Assembly, Orlando, Florida, May 3-7, 1996.	GU	10/13/93	Open
*9217 (1165)	The prostate cancer prevention trial: Efforts to increase the recruitment of minority participants. CM Moinpour. Poster presentation at the <u>Conference on the Recruitment and Retention of Minority Participants in Clinical Cancer Research</u> , Washington, DC, 1/26-27/1996.	GU	10/13/93	Open
9217 (1202)	The prostate cancer prevention trial. A Ryan. <u>Prevention/ Early Detection SIG Newsletter</u> 6(3):1, 1996.	GU	10/13/93	Open
9230 (1149)	Phase II trial of recombinant human interleukin-4 (rhIL-4) in patients with disseminated renal cell adenocarcinoma: A Southwest Oncology Group (SWOG) study. RP Whitehead, B Blumenstein, RC Flanigan, GR Weiss, DJ Culkin, SI Bearman, S Dakhil, ED Crawford. <u>American Society of Clinical Oncology</u> 15:259 (#672), 1996.	GU	6/1/93	5/1/95
*9235 (1150)	Phase II trial of casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study (SWOG 9235). O Kucuk, B Blumenstein, C Moinpour, D Lew, D Coleman, M Eisenberger, D Crawford. <u>American Society of Clinical Oncology</u> 15:245 (#618), 1996.	GU	12/15/93	6/1/94

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8494/8894 (1157)	Overview analysis issues using combined androgen deprivation overview analysis as an example. B Blumenstein. <u>Urologic Oncology</u> 1:95-100, 1995.	GU		
8708 (878)	Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate: A Southwest Oncology Group study. ME Marshall, MK Wolf, ED Crawford, GR Weiss, F Ahmann, FJ Meyers, B Blumenstein, M Eisenberger, AB Einstein. <u>American Journal of Clinical Oncology</u> 18(5):400-402, 1995.	GU Dev Ther	4/1/89	9/1/90
8719 (1093)	Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. SK Williamson, MK Wolf, MA Eisenberger, M O'Rourke, W Brannon, ED Crawford. <u>Investigational New Drugs</u> 13:167-170, 1995.	GU	11/1/88	5/15/93
8795 (1102)	Randomized Intergroup comparison of bacillus calmette-guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group study. DL Lamm, BA Blumenstein, ED Crawford, JD Crissman, BA Lowe, JA Smith Jr, MF Sarosdy, PF Schellhammer, AI Sagalowsky, EM Messing, P Loehrer, HB Grossman. <u>Urologic Oncology</u> 1:119-126, 1995.	GU	12/1/88	5/15/92
8824 (904)	A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: A Southwest Oncology Group study. RP Whitehead, MK Wolf, DL Solanki, GP Hemstreet III, P Benedetto, SP Richman, RC Flanigan, ED Crawford. <u>Journal of Immunotherapy</u> 18(2):104-114, 1995.	GU	5/1/89	8/15/91
9012 (438)	Evaluation of low dose alpha-interferon (Roferon-A®) in patients with advanced renal cell carcinoma: A Southwest Oncology Group study. ME Marshall, M Wolf, ED Crawford, IM Thompson, R Flanigan, SP Balcerzak, FJ Meyers. <u>Cancer Biotherapy</u> 10(3):205-209, 1995.	GU	5/1/91	5/1/92
9217 (1117)	Chemoprevention of prostate cancer. IM Thompson, CA Coltman, OW Brawley, A Ryan. <u>Seminars in Urology</u> 13(2):122-129, 1995.	GU	10/13/93	Open
9217 (1110)	Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C Coltman. In: <u>Important Advances in Oncology</u> VT DeVita, S Hellman, SA Rosenberg, eds, J.B. Lippincott Company pp. 57-76, 1995.	GU	10/13/93	Open

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9217 (1027)	Design of the prostate cancer prevention trial (PCPT). P Feigl, B Blumenstein, I Thompson, J Crowley, M Wolf, BS Kramer, CA Coltman Jr, OW Brawley, LG Ford. <u>Controlled Clinical Trials</u> 16:150-163, 1995.	GU	10/13/93	Open
Multiple Studies (1181)	Recent American multicenter trials for patients with metastatic prostate cancer. E DeAntoni, ED Crawford. <u>Urologe (A)</u> 34:382-388, 1995.	GU		
Multiple Studies (1049)	Southwest Oncology Group strategies in prostatic carcinoma. ED Crawford, M Hussain, EP DeAntoni, IM Thompson, MA Eisenberger, B Blumenstein, CA Coltman Jr. <u>Seminars in Surgical Oncology</u> 11:60-64, 1995.	GU		
None (1121)	Immunotherapy of superficial bladder carcinoma. MF Sarosdy. <u>AUA Update Series</u> , Lesson 29, 14:234-240, 1995.	GU		

ABSTRACTS PUBLISHED/PRESENTED

*8894 (INT-0105) (1088)	The prognostic significance of prostate specific antigen (PSA) in stage D ₂ prostate cancer (PC) interim evaluation of intergroup study 0105. M Eisenberger, ED Crawford, D McLeod, M Hussain, P Loehrer, B Blumenstein. <u>ASCO</u> 14:235 (#613), 1995.	GU	12/15/89	9/15/94
*9217 (1115)	Chemoprevention of prostate cancer with finasteride: An Intergroup trial. CA Coltman Jr, J Unger, IM Thompson. <u>Cancer Investigation</u> 13 (Suppl 1):43 (#36), 1995.	GU	10/13/93	Open

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8494 (INT-0036) (1090)	Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT.0036). MA Eisenberger, ED Crawford, M Wolf, B Blumenstein, DG McLeod, R Benson, FA Dorr, M Benson, JT Spaulding. <u>Seminars in Oncology</u> 21(5):613-619, 1994.	GU	3/18/85	7/1/87
8509 (442)	Phase II trial of menogaril in metastatic adenocarcinoma of the prostate: A Southwest Oncology Group study. SA Taylor, B Blumenstein, RL Stephens, ED Crawford, B Pistone, JB Hill. <u>Investigational New Drugs</u> 12:67-70, 1994.	GU Dev Ther	09/27/85	09/01/88
8509/8708 8719/8722 8955 (951)	Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. M Hussain, M Wolf, E Marshall, ED Crawford, M Eisenberger. <u>Journal of Clinical Oncology</u> 12(9):1868-1875, 1994.	GU		
8722 (880)	Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study. ME Marshall, B Blumenstein, ED Crawford, IM Thompson, JB Craig, M Eisenberger, F Ahmann. <u>American Journal of Clinical Oncology</u> 17(6):514-515, 1994.	GU Dev Ther	11/1/87	4/1/89
8794 (INT-0086) (1020)	An opportunity to determine optimal treatment of pT3 prostate cancer: The window may be closing. IM Thompson, JC Paradelo, ED Crawford, CA Coltman, B Blumenstein. <u>Urology</u> 44(6):804-811, 1994.	GU	8/15/88	Open
8926 (906)	Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma: A Southwest Oncology Group study. JA Kish, M Wolf, ED Crawford, JT Leimert, A Bueschen, JR Neeffe, RC Flanigan. <u>Cancer</u> 74(3):916-919, 1994.	GU	10/1/89	2/15/91
8929 (995)	Phase II evaluation of merbarone in renal cell carcinoma. RC Flanigan, JH Sakers, M Wolf, EH Kraut, AY Smith, B Blumenstein, ED Crawford. <u>Investigational New Drugs</u> 12(2):147-149, 1994.	GU	4/15/90	8/1/92
9217 (1068)	Prostate cancer prevention: Risk reduction through life-style, diet, and chemoprevention. KE Greco, L Kulawiak. <u>Oncology Nursing Forum</u> 21(9):1504-1511, 1994.	GU	10/13/93	Open
9217 (1070)	The prostate cancer prevention trial. A low-risk, high-accrual study. J O'Connor. <u>Oncology Issues</u> 9(5):20-24, 1994.	GU	10/13/93	Open

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

*8894 (INT-0105) (990)	Treatment of histologically confirmed D2 prostate cancer - a comparison of bilateral orchiectomy with or without flutamide. ED Crawford, MA Eisenberger, B Blumenstein, DG McLeod, DJ Culkin, AJ Bueschen, IM Thompson, BA Lowe. <u>Urology</u> 151(5):238A (#44), 1994.	GU	1215/89	Open
*9217 (1009)	Chemoprevention of prostate cancer with finasteride, an Intergroup trial. CA Coltman Jr, J Unger, IM Thompson. <u>Annals of Oncology</u> 5 (Suppl 8):65 (#P324), 1994. Corrigendum, <u>Annals of Oncology</u> 6(6):621, 1995.	GU	8/15/88	Open

*Presented.

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8231 (511)	Alternating combination chemotherapy in patients with extragonadal germ cell tumors: A Southwest Oncology Group study. RM Bukowski, M Wolf, BG Kulander, J Montie, ED Crawford, B Blumenstein. <u>Cancer</u> 71(8): 2631-2638, 1993.	GU	04/25/83	10/15/86
8302 (516)	Doxorubicin, mitomycin-C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate. A Southwest Oncology Group study. B Blumenstein, ED Crawford, JH Saiers, RL Stephens, SE Rivkin, CA Coltman, Jr. <u>Journal of Urology</u> 150:411-413, 1993.	GU	07/26/83	08/17/84
8325 (774)	Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study. RM Bukowski, M Wolf, HS Levine, ED Crawford, RL Stephens, E Gaynor, WG Harker. <u>JCO</u> 11:161-165, 1993.	GU Dev Ther	01/19/84	07/01/89
8421 (870)	Cyclophosphamide, methotrexate and 5-fluorouracil in the treatment of metastatic prostate cancer: A Southwest Oncology Group study. AJ Wozniak, BA Blumenstein, ED Crawford, M Boileau, SE Rivkin, WS Fletcher. <u>Cancer</u> 71(12):3975-3978, 1993.	GU	01/11/85	09/27/85
8494 (INT-0036) (970)	The use of flutamide in hormone-refractory metastatic prostate cancer. DG McLeod, RC Benson, Jr, MA Eisenberger, ED Crawford, BA Blumenstein, D Spicer, JT Spaulding. <u>Cancer Supplement</u> 72(12): 3870-3873, 1993.	GU	03/18/85	07/01/87
8494/8894 (INT-0036) (INT-0105) (969)	Some statistical considerations for the interpretation of trials of combined androgen therapy. BA Blumenstein. <u>Cancer Supplement</u> 72(12):3834-3840, 1993.	GU		
8789 (883)	Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: A multi-institutional study. DF Bajorin, MF Sarosdy, DG Pfister, M Mazumdar, RJ Motzer, HI Scher, NL Geller, WR Fair, H Herr, P Sogani, J Sheinfeld, P Russo, V Vlamis, R Carey, NJ Vogelzang, ED Crawford, GJ Bosi. <u>JCO</u> 11(4):598-606, 1993.	GU	08/15/88	12/15/90
8802 (884)	Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma: A Southwest Oncology Group study. ME Marshall, MK Wolf, ED Crawford, S Taylor, B Blumenstein, R Flanigan, FJ Meyers, HE Hynes, B Barlogie, M Eisenberger. <u>IND</u> 11:207-209, 1993.	GU Dev Ther	01/15/89	07/15/90

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9217 (937)	Chemoprevention of prostate cancer with finasteride. I Thompson, P Feigl, C Coltman. <u>Cancer Prevention</u> Dec:1-15, 1993.	GU		
None (802)	How PSA testing has improved and complicated therapeutic decision-making. ED Crawford, IM Thompson, PT Scardino. <u>Oncology</u> 13:15-17, 1993.	GU		
ABSTRACTS PUBLISHED/PRESENTED				
8221 (671)	Pre-operative irradiation plus radical cystectomy versus surgery alone for invasive bladder cancer: Final results of a randomized, prospective Southwest Oncology Group study. JA Smith, Jr, ED Crawford, BL Blumenstein, J Paradelo, BR Herschman. <u>American Urological Association, Inc.</u> 149:316A (#415), 1993.	GU	10/29/82	11/15/89
8795 (676)	A randomized comparison of bacillus calmette-guerin and mitomycin C prophylaxis in stage TA and T1 transitional cell carcinoma of the bladder. DL Lamm, ED Crawford, B Blumenstein, J Crissman, R deVere White, M Wolf, B Lowe, M Sarosdy, P Schellhammer, A Sagalowsky, J Smith, HB Grossman, R Flanigan, T Moon, C Brendler, C Coltman, Jr. <u>American Urological Association, Inc</u> 149:4 (#275), 1993.	GU	12/01/88	05/15/92
8824 (678)	A phase II trial of continuous infusion recombinant interleukin-2 (rIL-2) in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. RP Whitehead, MK Wolf, DL Solanki, P Benedetto, RC Flanigan, ED Crawford. <u>ASCO</u> 12:253 (#799), 1993.	GU	05/01/89	08/15/91
8956 (681)	Evaluation of cisplatin + 5 fluorouracil infusion for advanced/metastatic transitional cell carcinoma of the bladder (AMTCCB). A Southwest Oncology Group study. JA Kish, M Wolf, S Taylor, A Einstein, ED Crawford. <u>AACR</u> 34:203 (#1214), 1993.	GU	10/01/90	05/15/92
8997 (INT) (1038)	Phase III study of cisplatin (P) plus etoposide (VP16) with either bleomycin (B) or ifosfamide (I) in advanced stage germ cell tumors (GCT): An Intergroup trial. PJ Loehrer, LH Einhorn, P Elson, SD Williams, K Havlin, NJ Vogelzang, ED Crawford, DL Trump. <u>ASCO</u> 12:261 (#831), 1993.	GU	10/1/89	4/9/92
Multiple Studies (685)	Effects of prior hormone therapy on response and survival in Southwest Oncology Group phase II chemotherapy trials. M Hussain, M Wolf, E Marshall, ED Crawford, M Eisenberger. <u>ASCO</u> 12:243 (#760), 1993.	GU		
None (898)	In the era of prostate specific antigen (PSA), is prostate acid phosphatase (PAP) necessary for staging prostate cancer? A Southwest Oncology Group study. IM Thompson, EJ Zeidman, ED Crawford, AI Sagalowski, PF Schellhammer, RW deVere White, HB Grossman, E Klein, BA Lowe, AJ Bueschen, PT Scardino, RC Flanigan. <u>American Urological Association, Inc.</u> 149:308A (#360), 1993.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8104 (430)	Treatment of stages B3 and C seminoma with chemotherapy followed by irradiation therapy. A Southwest Oncology Group study. ED Crawford, P Goodman, WL Nabors, RL Stephens, K Khan, LM Pass, AY Smith. <u>Urology</u> 39(5):457-460, 1992.	GU	12/21/81	08/01/86
8308 (436)	Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer, phase II. A Southwest Oncology Group study. FJ Meyers, B Blumenstein, ED Crawford, HE Hynes, JE Montie, SA Taylor, HB Grossman, RB Natale. <u>Journal of Urology</u> 148:52-54, 1992.	GU Dev Ther	10/18/83	03/14/86
8517 (444)	Phase II study of platinum and mitoxantrone in meta-static prostate cancer: A Southwest Oncology Group study. CK Osborne, BA Blumenstein, ED Crawford, GR Weiss, RM Bukowski, NR Larrimer. <u>EJC</u> 28:477-478, 1992.	GU	12/10/86	08/01/87
8594 (525)	A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. PJ Loehrer, Sr, LH Einhorn, PJ Elson, ED Crawford, P Kuebler, I Tannock, D Raghaven, R Stuart-Harris, MF Sarosdy, BA Lowe, B Blumenstein, D Trump. <u>JCO</u> 10(7):1066-1073, 1992.	GU	10/84	05/15/89
8728 (458)	Phase II evaluation of didemnin B in advanced adeno-carcinoma of the kidney: A Southwest Oncology Group study. SA Taylor, P Goodman, ED Crawford, WJ Stuckey, RL Stephens, ER Gaynor. <u>IND</u> 10:55-56, 1992.	GU Dev Ther	01/01/88	02/01/89
8945 (547)	Phase II evaluation of piroxantrone in renal cell carcinoma: A Southwest Oncology Group study. A Allen, M Wolf, ED Crawford, MP Davis, RB Natale, ML Barnett. <u>IND</u> 10:129-132, 1992.	GU Dev Ther	09/01/90	05/01/91

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8494 (822)	A comparison of leuprolide and flutamide vs leuprolide alone in newly diagnosed stage D2 prostate cancer: Prognostic and therapeutic importance of the minimal disease subset. M Eisenberger, ED Crawford, D McLeod, R Benson, A Dorr, B Blumenstein. <u>ASCO</u> 11:201 (#619), 1992.	GU Dev Ther	03/18/85	07/01/87
8504/8617 8716/8802 8728/8707 (823)	Prognostic factors in patients with advanced renal cell carcinoma (RCC): The Southwest Oncology Group experience. ME Marshall, P Goodman, P Kuebler, R Flanigan, ED Crawford. <u>ASCO</u> 11:206 (#638), 1992.	GU		
*8507 (824)	Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study. DL Lamm, ED Crawford, B Blumenstein, MF Sarosdy, HB Grossman, RD Bohl, B Lowe, TD Moon, WL Weems, TM Beck, J Montie, JA Smith, J Crissman, CA Coltman, Jr. <u>ASCO</u> 11:203 (#627), 1992.	GU	12/20/85	12/15/88
8794 (INT-0086) (837)	Adjuvant radiotherapy following radical prostatectomy for pathologic stage C adenocarcinoma of the prostate: Initial evaluation of toxicity. I Thompson, ED Crawford, G Miller, J Paradelo, B Blumenstein, M Wolf, C Moinpour, K Hayden. <u>ASCO</u> 11:212 (#663), 1992.	GU	08/15/88	Open
8802 (838)	Phase II trial of echinomycin in advanced renal cell carcinoma: A Southwest Oncology Group study. ME Marshall, S Taylor, M Wolf, R Flanigan, B Blumenstein, ED Crawford. <u>ASCO</u> 11:206 (#637), 1992.	GU Dev Ther	01/15/89	07/15/90
8956 (844)	Significant response rate to cisplatin + 5-fluorouracil in advanced/recurrent bladder cancer. A preliminary report. A Southwest Oncology Group study. JA Kish, PF Schellhammer, M Wolf, AB Einstein, Jr. <u>ASCO</u> 11:219 (#692), 1992.	GU	10/01/90	Open
None (849)	Comparison of flow cytometry in quantitative florescence image analysis of superficial bladder cancer. BA Blumenstein, RW deVere White, GP Hemstreet. <u>American Urological Association, Inc.</u> #848, 1992.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7916 (427)	Gallium Nitrate in advanced bladder carcinoma. A Southwest Oncology Group study. ED Crawford, JH Sakers, LH Baker, JH Costanzi, R Bukowski. <u>Urology</u> 38(4):355-357, 1991.	GU	07/20/79	01/19/84
7990 (484)	Staging relationships and outcome in early stage testicular cancer: A report from the testicular cancer intergroup study. DG McLeod, RB Weiss, DM Stablein, FM Muggia, DF Paulson, JH Ellis, JT Spaulding, JP Donohue. <u>Journal of Urology</u> 145:1178-1183, 1991.	GU	06/22/79	03/22/85
8110 (387)	A randomized trial of cisplatin, vinblastine, and bleomycin vs vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: A Southwest Oncology Group study. AJ Wozniak, MK Samson, NT Shah, ED Crawford, CD Ford, SJ Altman, RL Stephens, RB Natale, BA Bouroncle, BA Blumenstein, GD Cummings. <u>JCO</u> 9(1):70-76, 1991.	GU	04/26/82	08/01/86
8216/38 (433)	A randomized clinical trial of intravesical doxorubicin immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. A Southwest Oncology Group study. DL Lamm, BA Blumenstein, ED Crawford, JE Montie, P Scardino, HB Grossman, TH Stanisic, JA Smith, J Sullivan, MF Sarosdy, JD Crissman, CA Coltman, Jr. <u>NEJM</u> 325:1205-1209, 1991.	GU	12/01/82	02/15/90
8716 (455)	Phase II evaluation of amonafide in renal cell carcinoma: A Southwest Oncology Group study. CS Higano, P Goodman, JB Craig, JA Kish, SE Rivkin, B Blumenstein, ED Crawford. <u>IND</u> 9:361-363, 1991.	GU	11/01/87	11/15/88
8788 (493)	Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. CR Nichols, SD Williams, PJ Loehrer, FA Greco, ED Crawford, J Weetlauffer, ME Miller, A Bartolucci, L Schacter, LH Einhorn. <u>JCO</u> 9(7):1163-1172, 1991.	GU	01/15/88	09/15/89

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

*7916 (559)	Treatment of advanced transitional cell carcinoma (TCC) of the bladder with constant infusion Gallium Nitrate. PA Seligman, ED Crawford. <u>ASCO</u> 10:168 (#534), 1991.	GU	07/20/79	01/19/84
*8789 (504)	A randomized trial of etoposide + carboplatin (EC) vs. etoposide + cisplatin (EP) in patients (PTS) with metastatic germ cell tumors (GCT). DF Bajorin, MF Sarosdy, GJ Bosi, S Welsen, G Heller. <u>ASCO</u> 10:168 (535), 1991.	GU	08/15/88	12/15/90
8926 (415)	Efficacy of low dose continuous infusion 5-fluorouracil (LDCI-5FU) in recurrent/metastatic (r/m) renal cell carcinoma (RCC). A Southwest Oncology Group study. JA Kish, JR Neefe, R Flanigan. <u>AACR</u> 32:186 (#1107), 1991.	GU	10/01/89	02/15/91

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8216/38	Fatal sepsis following intravesical bacillus calmette-guerin administrations for bladder cancer. WH Rawls, DL Lamm, BA Lowe, ED Crawford, MF Sarosdy, JE Montie, HB Grossman, PT Scardino. <u>Urology</u> 144:1328-1330, 1990.	GU	12/01/82	02/15/90
8219 (305)	Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. CK Osborne, B Blumenstein, ED Crawford, CA Coltman, Jr, AY Smith, BW Lambuth, RA Chapman. <u>JCO</u> 8(10):1675-1682, 1990.	GU	08/11/84	10/01/86
8494	Combined androgen blockade: Leuprolide and flutamide versus leuprolide and placebo. ED Crawford, P Goodman, B Blumenstein. <u>Seminars in Urology</u> 8(3):154-158, 1990.	GU	03/18/85	07/01/87
8504 (329)	Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study. RL Stephens, P Goodman, ED Crawford, CF Spicer, BA Lowe, FR Ahmann, R Chapman, RB Natale. <u>IND</u> 8:S69-S71, 1990.	GU	09/27/85	01/15/87
8519 (331)	Methylglyoxal bis-guanylhydrazone in advanced bladder cancer. DD Von Hoff, BA Blumenstein, TW Pollock, ED Crawford, JK Weick, JT Guy, M Eisenberger, WS Fletcher, RB Natale. <u>EJC</u> 26(7):848-849, 1990.	GU	01/86	05/15/89
8617 (341)	Phase II trial of high dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study. RM Bukowski, P Goodman, ED Crawford, JS Sergi, BG Redman, RP Whitehead. <u>JNCI</u> 82(2):143-146, 1990.	GU	03/15/87	08/15/88
8707 (343)	Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma: A Southwest Oncology Group study. JP Kuebler, PJ Goodman, TD Brown, ED Crawford, CL Reitz, WA Knight, III, JA Kish. <u>IND</u> 8:307-309, 1990.	GU	06/01/87	01/01/88
None	Editorial on the importance of clinical trials. ED Crawford. <u>Journal of Urology</u> 143(4):787, 1990.	GU		
None	Quality of life assessment in Southwest Oncology Group trials. CM Moinpour, K Hayden, IM Thompson, P Feigl, B Metch. <u>Oncology</u> 4(5):79-89, 1990.			

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8216/38 (353)	Effect of colony-forming unit dose of connaught BCG on outcome to immunotherapy in superficial bladder cancer: A Southwest Oncology Group study. B Blumenstein, D Lamm, MAS Jewett, G Humphries, L Boux, J Montie, P Scardino, H Grossman, ED Crawford, JA Smith, T Stanisic. <u>Journal of Urology</u> 143(4):340A, (#608), 1990.	GU	12/01/82	12/20/85
*8325 (357)	Cisplatin (CDDP) and mitotane in metastatic adrenal carcinoma: A Southwest Oncology Group study. RM Bukowski, J Montie, ED Crawford, M Wolf. <u>ASCO</u> 9:136 (#527), 1990.	GU	01/19/84	07/01/89
*8494 (361)	Evaluation of "complete androgen blockade" (CAB) with flutamide (F) added to leuprolide (L) after progression on leuprolide (L) alone: Results of INT-0036 study in stage D2 cancer of the prostate (CP). D McLeod, B Blumenstein, M Eisenberger, ED Crawford, D Spicer, J Spaulding, A Dorr, R Benson. <u>ASCO</u> 9:136 (#526), 1990.	GU	03/18/85	07/01/87
*8594 (363)	Advanced bladder cancer: A prospective intergroup trial comparing single agent cisplatin (CDDP) vs. M-VAC combination therapy (INT-0078). PJ Loehrer, P Elson, JP Kuebler, ED Crawford, I Tannock, D Raghavan, R Stuart-Harris, D Trump, LH Einhorn. <u>ASCO</u> 9:132 (#511), 1990.	GU	04/15/86	05/15/89
*8788 (373)	Phase III study of cisplatin dose intensity in advanced germ cell tumors (GCT): A Southeastern and Southwest Oncology Group protocol. L Einhorn, S Williams, P Loehrer, ED Crawford, J Wettlaufer, A Bartolucci, L Schacter. <u>ASCO</u> 9:132 (#510), 1990.	GU	01/15/88	09/15/89
Multiple Studies (379)	Evaluation of chemotherapy (CT) in endocrine resistant prostate cancer (ERPC) patients (PTS) with measurable (MD) versus bone disease only (BDO): The Southwest Oncology Experience. M Eisenberger, B Blumenstein, P Scardino, ED Crawford. <u>ASCO</u> 9:153 (#596), 1990.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8026	Cis-diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: A Southwest Oncology Group study. RG Gagliano, BA Blumenstein, ED Crawford, RL Stephens, CA Coltman, Jr, JJ Costanzi. <u>J Urol</u> 141:66-67, 1989.	GU	09/19/80	08/01/86
8494	A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. ED Crawford, MA Eisenberger, DG McLeod, JT Spaulding, R Benson, FA Dorr, BA Blumenstein, MA Davis, PJ Goodman. <u>N Engl J Med</u> 321:419-424, 1989.	GU	03/18/85	07/01/87
ABSTRACTS PUBLISHED/PRESENTED				
8110	A randomized trial of cisplatin (P), vinblastine (VLB) plus either bleomycin (PVB), or VP-16 (VPV) in patients with advanced testicular cancer. MK Samson, ED Crawford, S Altman, R Natale, NT Shah, B Blumenstein. <u>ASCO</u> 8:134 (#522), 1989.	GU	04/26/82	08/01/86
*8216/38	BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study. DL Lamm, J Crissman, ED Crawford, B Blumenstein, JE Montie, PT Scardino, HB Grossman, T Staniscic, JA Smith, M Sarosdy. <u>ASCO</u> 8:130 (#504), 1989.	GU	12/01/82	12/20/85
*8494	Significance of pre-treatment stratification by extent of disease (ED) in stage D2 prostate cancer (PC) patients treated with leuprolide + flutamide (LF) or leuprolide + placebo (LP). M Eisenberger, ED Crawford, B Blumenstein, R Benson, D McLeod, A Dorr, J Spaulding. <u>ASCO</u> 8:132 (#515), 1989.	GU	03/18/85	07/01/87
8617	Phase II evaluation of recombinant interleukin-2 (rIL-2) in metastatic renal cell carcinoma (RCC): SWOG-8617. RM Bukowski, P Goodman, ED Crawford, JS Sergi, L Baker, J Neidhart. <u>ASCO</u> 8:143 (#556), 1989.	GU	03/15/87	08/15/88
8707	Continuous infusion recombinant gamma interferon (CIR-GIFN) for renal cell carcinoma (RCC). J Kuebler, T Brown, P Goodman, D Crawford, C Reitz, W Knight, J Kish. <u>ASCO</u> 8:140 (#544), 1989.	GU	06/01/87	01/01/88

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8716	A phase II trial of amonafide in advanced renal cell carcinoma. CS Higano, J Craig, P Goodman, B Blumenstein, J Wettlaufer, ED Crawford. <u>ASCO</u> 8:147 (#574), 1989.	GU	11/01/87	11/15/88
8722	Phase II trial of amonafide in advanced prostate cancer: A Southwest Oncology Group study. J Craig, E Crawford. <u>ASCO</u> 8:147 (#573), 1989.	GU	11/01/87	04/01/89
8728	Phase II trial of didemnin B (Did-B) in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study. S Taylor, B Pistone, RL Stephens, ED Crawford. <u>ASCO</u> 8:145 (#564), 1989.	GU	01/01/88	02/01/89

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7990	The clinical significance of unconventional orchiectomy approaches in testicular cancer: A report from the testicular cancer intergroup study. JK Giguere, DM Stablein, JT Spaulding, DG McLeod, DF Paulson, RB Weiss. <u>J Urol</u> 139:1225-1228, 1988.	GU	06/22/79	03/22/85
7990	Toxicity comparison between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer. RB Weiss, DM Stablein, FM Muggia, LH Einhorn, RB Golbey, WD DeWys. <u>Cancer</u> 62(1):18-23, 1988.	GU	06/22/79	03/22/85
8602	A phase II clinical trial of interleukin-2 and lymphokine activated killer cells in metastatic renal cancer. RI Fisher, CA Coltman, Jr, JH Doroshow, AA Rayner, MJ Hawkins, JW Mier, P Wiernik. <u>Annals Internal Medicine</u> 108:518-523, 1988.	GU	04/07/86	
ABSTRACTS PUBLISHED/PRESENTED				
8231	Phase II trial of alternating combination chemotherapy in patients with extragonadal germ cell tumors: A Southwest Oncology Group study (SWOG 8231). RM Bukowski, J Montie, D Crawford. <u>ASCO</u> 7:133 (#516), 1988.	GU	04/25/83	10/15/86
*8494	Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, Intergroup study 0036. E Crawford, D McLeod, A Dorr, J Spaulding, R Benson, M Eisenberger, B Blumenstein. <u>ASCO</u> 7:119 (#460), 1988.	GU	03/18/88	07/01/87

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7990	Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. SD Williams, DM Stablein, LH Einhorn, FM Muggia, RB Weiss, JP Donohue, DF Paulson, KW Brunner, EM Jacobs, JT Spaulding, W DeWys, ED Crawford. <u>NEJM</u> 317:1433-1438, 1987.	GU	06/22/79	03/22/85
7990	Early stage testis cancer: The testicular cancer intergroup studies. Adjuvant chemotherapy of testicular cancer. SD Williams, D Stablein, F Muggia, LH Einhorn, R Hahn, JP Donohue, K Brunner, W DeWys, D Crawford, S Spaulding, RB Weiss, R Golbey, EM Jacobs. In <u>Adjuvant Therapy of Cancer V</u> . Sydney E. Salmon (Ed). New York, Grune & Stratton, pp. 587-592, 1987.	GU	06/22/79	03/22/85
8101	Teniposide in metastatic renal and bladder cancer: A Southwest Oncology Group study. N Oishi, J Berenberg, BA Blumenstein, K Johnson, SE Rivkin, RM Bukowski, RM O'Bryan, RL Stephens, J Quagliana, JH Saiers, ED Crawford. <u>Cancer Treat Rep</u> 71(12):1307-1308, 1987.	GU	07/31/81	01/11/85
8217	Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: A Southwest Oncology Group study. JH Saiers, B Blumenstein, M Slavik, JJ Costanzi, ED Crawford. <u>Cancer Treat Rep</u> 71(12):1305-1306, 1987.	GU	08/11/82	03/22/85
8221	Preoperative radiation therapy in the treatment of bladder cancer. ED Crawford, S Das, JA Smith, Jr. <u>Urol Clinics of North Am</u> 14(4):781-787, 1987.	GU	10/29/82	11/15/89
8316	Evaluation of fludarabine phosphate in renal cell carcinoma: A Southwest Oncology Group study. L Balducci, B Blumenstein, DD Von Hoff, M Davis, HE Hynes, RM Bukowski, ED Crawford. <u>Cancer Treat Rep</u> 71(5):543-544, 1987.	GU	04/20/84	03/22/85

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8110	A randomized clinical trial comparing cisplatin, vinblastine plus either bleomycin (PVB) or VP-16 (VPV) and surgical resection of residual disease in advanced testicular cancer: A Southwest Oncology Group study. ED Crawford, MK Samson, R Natale, NT Shaw, B Blumenstein, MA Davis. <u>Journal of Urology</u> 137(4):212A (#436), 1987.	GU	04/26/82	08/01/86
8494	A comparison of leuprolide (L) with flutamide (F) and leuprolide in previously untreated patients with clinical stage D2 cancer of the prostate, phase III, Intergroup study-0036. ED Crawford, D McLeod, A Dorr, J Spaulding, R Benson, M Eisenberger, B Blumenstein. Presented at the <u>66th Annual Meeting of the South Central Section of the American Urologic Association, Inc.</u> , London, England, October 25-28, 1987.	GU	03/18/85	07/01/87

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7990	Resectable stage II testicular carcinoma: A randomized comparison of post-lymphadenectomy chemotherapy and initial observation - A Cooperative Intergroup study. JT Spaulding, DM Stablein, LH Einhorn, JP Donohue, FM Muggia, K Cummings, ED Crawford, R Weiss, DF Paulson, EM Jacobs. <u>Am J Clin Oncol</u> 9:103, 1986.	GU	06/22/79	03/22/85
8207	High dose AZQ in renal cancer. A Southwest Oncology Group phase II study. RL Stephens, R Kirby, ED Crawford, R Bukowski, SE Rivkin, RM O'Bryan. <u>Invest New Drugs</u> 4:57-59, 1986.	GU	07/09/82	03/16/84
8216/38 (1299)	A trial of bacillus calmette-guerin versus adriamycin in superficial bladder cancer: A South-West Oncology Group study. K Mori, DL Lamm, ED Crawford. <u>Urology Internationalis</u> 41(4):254-259, 1986.	GU		
ABSTRACTS PUBLISHED/PRESENTED				
7990	Resected stage II testicular cancer: immediate adjuvant chemotherapy versus observation. S Williams, F Muggia, L Einhorn, R Hahn, J Donohue, K Brunner, D Stablein, W DeWys, D Crawford, J Spaulding. <u>ASCO</u> 5:90 (#380), 1986.	GU	06/22/79	03/22/85
7990	Toxicity of chemotherapy as adjuvant or salvage treatment in early stage nonseminomatous testicular cancer (NSTC). RB Weiss, DM Stablein, FM Muggia, LH Einhorn, RL Stephens, JT Spaulding, WD DeWys. <u>ASCO</u> 5:99 (#384), 1986.	GU	06/22/79	03/22/85
8110	A randomized comparison of cisplatin, vinblastine (VLB) plus either bleomycin (PVB) or VP-16 (VPV) in patients with advanced testicular cancer. MK Samson, ED Crawford, R Natale, B Bouroncle, S Altman. <u>ASCO</u> 5:96 (#373), 1986.	GU	05/11/82	08/01/86
8217	Spirogermanium in the treatment of stage D2 adenocarcinoma of the prostate: A Southwest Oncology Group study. JH Saiers, M Slavik, J Costanzi, ED Crawford. <u>ASCO</u> 5:111 (#433), 1986.	GU	08/11/82	03/22/85

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8308	Combination cisplatin and dichloromethotrexate in advanced bladder cancer: A Southwest Oncology Group (SWOG) study. RB Natale, HB Grossman, ED Crawford, JR Borst, W Trantum, BA Blumenstein. <u>ASCO</u> 5:104 (#402), 1986.	GU	10/18/83	03/20/86

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7922	Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study. M Al-Sarraf, J Frank, JA Smith Jr., RM O'Bryan, JJ Costanzi, RL Stephens, J Caraveo, ED Crawford. <u>Cancer Treat Rep</u> 69:189-194, 1985.	GU	08/08/79	09/10/82
7945	Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: A Southwest Oncology Group study. R Shildt, RL Stephens, VP Subramanian, LH Baker, WS Fletcher, RM O'Bryan, JD McCracken. <u>Cancer Treat Rep</u> 69:709-710, 1985.	GU	06/04/81	05/05/82
7956	Infarction - nephrectomy for metastatic renal carcinoma. A Southwest Oncology Group study. JE Gottesman, ED Crawford, HB Grossman, P Scardino, JD McCracken. <u>Urology</u> 25(3): 248-50, 1985.	GU	02/09/80	01/19/84
8104	Treatment of stage cII (N4) and cIII seminoma with chemotherapy followed by irradiation therapy: A Southwest Oncology Group study. ED Crawford, R Stephens, N Oishi, K Khan, LM Pass. <u>J Urol</u> 133: 246A, 1985.	GU	12/21/81	08/01/86
ABSTRACTS PUBLISHED/PRESENTED				
8026	Cis-platinum in advanced squamous cell penile carcinoma: A Southwest Oncology Group study. R Gagliano, ED Crawford. <u>ASCO</u> , #C-375, 1985.	GU	09/15/80	08/01/86
8104	Treatment of stages cII (N4) and cIII seminoma with chemotherapy followed by irradiation therapy: A Southwest Oncology Group study. ED Crawford, R Stephens, N Oishi, K Khan, LM Pass. <u>J Urol</u> 133: 246A, 1985.	GU	12/21/81	01/19/84
8216/38	BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study. DL Lamm, ED Crawford. <u>ASCO</u> , #C-424, 1985.	GU	12/01/82	12/20/85
8216/38	BCG versus adriamycin in the treatment of transitional cell carcinoma in-situ: A Southwest Oncology Group study. <u>Proc AUA</u> 133:184A (#283), 1985.	GU	12/01/82	12/20/85

8216/38	Intravesical adriamycin for recurrent superficial bladder cancer: A Southwest Oncology Group study. ED Crawford, DL Lamm, JE Montie, PT Scardino, HB Grossman, T Staniscic, JA Smith, JW Sullivan. <u>Proc AUA</u> 133:213A (#397), 1985.	GU	12/01/82	12/20/85
8216/38	BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study. DL Lamm, ED Crawford. <u>Inter-American Society for Chemotherapy</u> , p. 49, #E7, 1985.	GU	12/01/82	12/20/85
8231	Phase II trial of combination chemotherapy in patients with extragonadal germ cell tumors: A Southwest Oncology Group study. RM Bukowski, J Montie. <u>AACR</u> , #658, 1985.	GU	09/29/82	10/15/86
8302	Treatment of Stage DII adenocarcinoma of the prostate with doxorubicin, mitomycin-C and 5-fluorouracil (DMF): A Southwest Oncology Group study. JH Saiers, BL Trantum, R Stephens, ED Crawford. <u>ASCO</u> , #C-423, 1985.	GU	07/26/83	08/17/84
8316	Evaluation of fludarabine phosphate (NSC 312887) in renal cell carcinoma: A Phase II study. L Balducci, MA Davis, ED Crawford, DD Von Hoff, J Gordon, TN Kim, A Bagley, S Wright, G Kajikawa, RM Bukowski, JF Boyd, DK Cash, FH Stutz, GT Budd, SR Dakhil, HS Eyre, BW Dana, WS Fletcher, HE Hynes. <u>ASCO</u> , #C-429, 1985.	GU	04/20/84	03/22/85

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7630	Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. RL Stephens, C Vaughn, M Lane, J Costanzi, R O'Bryan, SP Balcerzak, H Levin, J Frank, CA Coltman Jr. <u>Cancer</u> 53:406-410, 1984.	GU		
7817	Dose-response and dose-survival advantage for high versus low-dose Cisplatin combined with Vinblastine and Bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. MK Samson, SE Rivkin, SE Jones, JJ Costanzi, AF LoBuglio, RL Stephens, EA Gehan, GD Cummings. <u>Cancer</u> 53:1029-1035, 1984.	GU		
7817	The Southwest Oncology Group study for advanced testicular cancer. ED Crawford. <u>Seminars in Urology</u> 2(4), 1984.	GU		
7904	A randomized trial of Hexamethylmelamine versus 5-FU, doxorubicin and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group study. RG Gagliano, RL Stephens, JJ Costanzi, N Oishi, WJ Stuckey, PN Grozea, J Frank, ED Crawford. <u>Cancer Treat Rep</u> 68:1025-1026, 1984.	GU		
8011	Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: A Southwest Oncology Group study. SA Taylor, DD Von Hoff, LH Baker, SP Balcerzak. <u>Cancer Treat Rep</u> 68:919-920, 1984.	GU		
8268	Interferon-a therapy of renal cancer. JA Neidhart, MM Gagen, D Young, R Tuttle, TJ Melink, A Ziccarrelli, D Kisner. <u>Cancer Res</u> 44:4140-4143, 1984.	GU		
Multiple Studies	Southwest Oncology Group experience with randomized protocols for bladder cancer. JA Smith Jr, ED Crawford. In: <u>Controlled Clinical Trials in Urologic Oncology</u> . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press, 249-254, 1984.	GU		

ABSTRACTS PUBLISHED/PRESENTED

7916	Treatment of metastatic bladder cancer with gallium nitrate. ED Crawford, JH Saiers, LH Baker. <u>13th International Congress of Chemotherapy</u> SE 12(1):7A, 1984.	GU		
7956	Infarction-nephrectomy for metastatic renal carcinoma. A Southwest Oncology Group study. JE Gottesman, ED Crawford, HB Grossman, PT Scardino. <u>Abstracts of the</u>	GU		

8101	VM-26 in advaced renal cell carcinoma - A Southwest Oncology Group study. N Oishi, M Inamasu, D Wachi, R Bukowski, S Rivkin, J Frank, C Coltman, D Crawford. <u>ASCO</u> , #C-598, 1984.	GU
*8110	Surgical resection of residual disease in advanced testicular cancer. ED Crawford, MK Sampson, R Klugo. Presented at the <u>48th Annual Meeting of the American Urological Association Inc.</u> , April 1-4, 1984.	GU
*8268	A Phase II trial of lymphoblastoid interferon (Wellferon™) in metastatic renal adenocarcinoma. A Southwest Oncology Group study. D Kisner, T Melink, A Ziccarrelli, M Gagen, R Tuttle, J Neidhart. <u>4th NCI-EORTC Symposium on New Drugs in Cancer Therapy</u> (Brussels, 1984). DD Von Hoff, ed. <u>Investigational New Drugs</u> 2:107, 1984.	GU
8268	Therapy of renal cancer with low (LD), intermediate (ID), and high (HD) dose regimens of human lymphoblastoid interferon (HBLI; Wellferon). J Neidhart, M Gagen, D Kisner, R Tuttle, J Whisnant. <u>ASCO</u> , #C-232, 1984.	GU

* Abstracts presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7525	The Southwest Oncology Group experience. Adjuvant therapy for stage IB and II non-seminomatous testicular cancer. RL Stephens, JR Eltringham, CA Coltman Jr, J Neidhart, J Mullins, J Frank. <u>Int J Rad Onc Bio Phys</u> 9:1885-1890, 1983.	GU		
7624	Adriamycin versus adriamycin plus cis-diamminedichloro-platinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study. R Gagliano, H Levin, MN El-Bolkainy, HE Wilson, RL Stephens, WS Fletcher, SE Rivkin, RM O'Bryan, CA Coltman Jr, JH Saiki, WJ Stuckey, L Balducci, JD Bonnet, DO Dixon. <u>Am J Clin Oncol (CCT)</u> 6(2): 215-218, 1983.	GU		
7959	Mitoguazone in advanced renal carcinoma. A Phase II trial of the Southwest Oncology Group. WA Knight III, A Drelichman, C Fabian, RM Bukowski. <u>Cancer Treat Rep</u> 67:1139-1140, 1983.	GU		
8010	Mitoxantrone: Modest activity in a Phase II trial in advanced prostate cancer. CK Osborne, A Drelichman, DD Von Hoff, ED Crawford. <u>Cancer Treat Rep</u> 67:1133-1135, 1983.	GU		

ABSTRACTS PUBLISHED/PRESENTED

*7302/7434/ 7801/7940	Southwest Oncology Group experience with 5-fluorouracil in carcinoma of the colon. JD McCracken, TT Chen, LP Leichman, VK Vaitkevicius. <u>13th International Congress of Chemotherapy</u> (Vienna, September 2, 1983), Part 259, SE 12.1, 20-8, 1983.	GU		
7904	Hexamethylmelamine (HEX) vs. Fluorouracil, Adriamycin and Cytosin (FAC) in advanced bladder cancer - A SWOG study. ED Crawford, R Gagliano, J Frank. <u>ASCO</u> , #C-518, 1983.	GU		
7922	Combination of Cytosin, Adriamycin and Cis-platinum (CAP) vs. Phase II agent m-AMSA in patients with advanced and metastatic bladder cancer--A Southwest Oncology Group study. M Al-Sarraf. <u>AACR</u> , #558, 1983.	GU		
*8110	The role of surgical resection in the management of advanced testicular cancer: A Southwest Oncology Group study. ED Crawford, MK Sampson, R Klugo. <u>Abstracts of the American Urological Association</u> , p. 99, #134, 1983.	GU		

* Abstracts presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7520	Phase II trial of Dianhydrogalactitol (NSC-132313) in advanced renal carcinoma. A Southwest Oncology Group study. V Ratanatharathorn, LH Baker, L Balducci, RW Talley, B Hoogstraten. <u>Cancer Treat Rep</u> 66:1231-1232, 1982.	GU		
7805	Yoshi 864 plus Medroxyprogesterone Acetate (MPA) in adenocarcinoma of the kidney: A Southwest Oncology Group study. SJ Altman, RL Stephens, JD Bonnet. <u>Cancer Treat Rep</u> 66:1781-1782, 1982.	GU		

ABSTRACTS PUBLISHED/PRESENTED

7922	Combination of Cyclophosphamide, Adriamycin, and Cis-Platinum (CAP) versus m-AMSA in patients with advanced transitional bladder cancer. M Al-Sarraf. <u>ASCO</u> , #C-406, 1982.	GU		
7956	Infarction-nephrectomy for metastatic hypernephroma: A Southwest Oncology Group study. JE Gottesman, D Crawford, M Grossman, P Scardino. <u>13th International Cancer Congress</u> , 393, 1982.	GU		
8010	A Phase II clinical investigation of dihydroxyanthracenedione (DHAD) in patients with advanced prostatic cancer. A Drelichman, CK Osborne, DD Von Hoff. <u>ASCO</u> , #C-465, 1982.	GU		
8011	Phase II trial of dihydroxyanthracenedione (DHAD) in advanced renal cell carcinoma: A SWOG study. SA Taylor, DD Von Hoff. <u>ASCO</u> , #C-457, 1982.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7634	Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer: A Southwest Oncology Group study. RG Gagliano, FJ Panettiere, CD Haas, L Baker, J Hewlett, WJ Stuckey, RM O'Bryan, R Bottomley, LK Heilbrun. <u>Cancer Clin Trials</u> 4:401-405, 1981.	GU		
7716	Study of Tamoxifen in renal cell carcinoma and the influence of certain prognostic factors: A Southwest Oncology Group study. M Al-Sarraf, H Eyre, J Bonnet, J Saiki, R Gagliano, R Pugh, D Lehané, DO Dixon, R Bottomley. <u>Cancer Treat Rep</u> 65:447-451, 1981.	GU		

ABSTRACTS PUBLISHED/PRESENTED

?	Hormonal priming and chemotherapy for advanced prostate cancer: a pilot study. CK Osborne, DL Lamm, HM Radwin. <u>AACR</u> 22:461, 1981.	GU		
7817	Positive dose-response of high (H) versus low (L) dose cis-platinum (DDP), vinblastine (VLB) and bleomycin (Bleo) in disseminated germ cell neoplasms of the testis. MK Samson, RL Stephens, RC Klugo. <u>ASCO</u> , #C-538, 1981.	GU		
7959	A Phase II trial of Methyl-Glyoxal Bisguanylhydrazone (MGBG, Methyl-GAG) in renal carcinoma. A Southwest Oncology Group study. SK Callahan, WA Knight III. <u>AACR</u> , #649, 1981.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7610	Vinblastine (VLB), Bleomycin (BLEO), Cis-Diamminedichloroplatinum (DDP) in disseminated extragonadal germ cell tumors: A Southwest Oncology Group study. L Feun, M Samson, R Stephens. <u>Cancer</u> 45:2543-2549, 1980.	GU		
7610	Vinblastine, Bleomycin and Cis-Diamminedichloroplatinum in disseminated testicular cancer: Response to treatment and prognostic correlations: A Southwest Oncology Group study. MK Samson, R Fisher, RL Stephens, S Rivkin, M Opiari, T Maloney, CW Groppe. <u>European Journal of Cancer</u> 16:1359-1366, 1980.	GU		
7610	Probable cure of metastatic testicular tumors treated with sequential therapy. JA Neidhart, R Memo, EN Metz, H Wise. <u>Cancer Treat Rep</u> 64(4-5):553-558, 1980.	GU		
7803	Phase II trial of Baker's Antifol in metastatic renal cell carcinoma: A Southwest Oncology Group study. RM Bukowski, A LoBuglio, JD McCracken, R Pugh. <u>Cancer Treat Rep</u> 64(12):1387-1388, 1980.	GU		
ABSTRACTS PUBLISHED/PRESENTED				
7624	Adriamycin versus Adriamycin plus Cis-Platinum in transitional cell bladder carcinoma. A Southwest Oncology Group study. R Gagliano. <u>ASCO</u> , #C-110, 1980.	GU		
7860	Methyl-Glyoxal Bis-Guanylhydrazone (Methyl GAG, MGBG) in advanced renal carcinoma. WA Knight III, RB Livingston, CJ Fabian, JJ Costanzi. <u>ASCO</u> , #C-190, 1980.	GU		
7860	Chemotherapy of advanced renal adenocarcinoma with methylglyoxal-bis-guanylhydrazone (methyl-GAG). RF Todd, MB Garnick, GP Canellos. <u>AACR</u> , 21:340, 1980.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7610	Vinblastine, bleomycin, and cis-dichlorodiammine-platinum (II) in disseminated testicular cancer: Preliminary report of a Southwest Oncology Group study. MK Samson, RL Stephens, S Rivkin, M Pipari, T Maloney, CW Groppe, R Fisher. <u>Cancer Treat Rep</u> 63:1663-1667, 1979.	GU		
------	---	----	--	--

ABSTRACTS PUBLISHED/PRESENTED

7610	Vinblastine, Bleomycin and Cis-Platinum in disseminated estragonadal germ cell tumors. L Feun, M Samson. <u>ASCO</u> , #C-325, 1979.	GU		
7716	The clinical trial of Tamoxifen in patients with advanced renal cell cancer. M Al-Sarraf. <u>ASCO</u> , #C-360, 1979.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7303	Chemotherapy of disseminated germinal tumors of the testis - comparison of vinblastine and bleomycin with vincristine, bleomycin and actinomycin D. SC Spigel, RL Stephens, CD Haas, SE Jones, D Lehane, TE Moon, CA Coltman, Jr. <u>Cancer Treat Rep</u> 62(1):129-130, 1978.	GU		
------	--	----	--	--

ABSTRACTS PUBLISHED/PRESENTED

7610	Vinblastine (VLB), bleomycin (Bleo) and cis-diamminedichloroplatinum II (DDP) in disseminated testicular cancer. M Samson, R Stephens. <u>AACR</u> 19:12 (#47), 1978.	GU		
------	---	----	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

7438	Phase II evaluation of single high-dose cis-diamminedi-chloroplatinum (II) (NSC-119875, CACP) in gynecologic *GYN) and genitourinary (GU) neoplasia. AH Rossof, RW Talley and RL Stephens. <u>AACR</u> , #388, 1977.	GYN GU		
------	--	-----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

226	Porfiromycin (NSC 56410) in the management of epidermoid and transitional cell cancer: A Phase II study. FJ Panettiere, RW Talley, J Torres, M Lane. <u>Cancer Treat Rep</u> 60(7):907-911, 1976.	GU		
-----	---	----	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1974**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

7303	Combination chemotherapy of testicular carcinoma. SC Spigel and CA Coltman, Jr. <u>ASCO</u> , 1974.	GU		
------	--	----	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
7303	Combination chemotherapy of testicular carcinoma. SC Spigel, CA Coltman, Jr. <u>ASCO</u> , 1973.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Vinblastine in the management of testicular cancer. ML Samuels, CD Howe. <u>Cancer</u> 25:1009-1017, 1970.	GU		
?	Vinblastine sulfate in the treatment of germinal tumors of the testes. ML Samuels, CD Howe. <u>Xth International Cancer Congress Abstracts</u> , Houston, TX, May 1970. Medial Arts Publishing Co.:458, 1970.	GU		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Phase II studies of hydroxyurea (NSC-32065) in adults: Urologic and gynecologic neoplasms. CD Howe, ML Samuels. <u>Cancer Chemotherapy Reports</u> 40:47-48, 1964.	GU GYN		